Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Ph.D., New York University 1990
• 

  Medical Licensure

  • 2178. North Carolina. 1996
• 

  Previous Appointments & Affiliations

  • Professor of Psychology and Neuroscience, Psychology & Neuroscience, Trinity College of Arts & Sciences 2011 - 2022
  • Professor in Psychiatry and Behavioral Sciences, Psychiatry & Behavioral Sciences, Behavioral Medicine & Neurosciences, Psychiatry & Behavioral Sciences 2021 - 2022
  • Professor in Psychiatry and Behavioral Sciences, Psychiatry & Behavioral Sciences, Clinical Science Departments 2007 - 2020
  • Member in the Duke Clinical Research Institute, Duke Clinical Research Institute, Institutes and Centers 2016 - 2020
  • Associate Professor in Psychiatry and Behavioral Sciences, Psychiatry & Behavioral Sciences, Medical Psychology, Psychiatry & Behavioral Sciences 2005 - 2007
  • Associate Professor in Psychiatry and Behavioral Sciences, Psychiatry & Behavioral Sciences, Medical Psychology, Psychiatry & Behavioral Sciences 1997 - 2005
  • Assistant Professor in Psychiatry and Behavioral Sciences, Psychiatry & Behavioral Sciences, Medical Psychology, Psychiatry & Behavioral Sciences 1995 - 1997
• Recognition
• 

  In the News

  • NOV 19, 2019

    Global List of Highly Cited Puts Duke in Top Ten

  • NOV 27, 2018

    Duke Faculty Plentiful On ‘Highly Cited’ List

  • APR 24, 2014

    The News & Observer

    Richard Keefe: Bruce Springsteen offers chance to recall impulsiveness of teen brains
• Expertise
• 

  Global Scholarship

  • Expertise

    • Singapore (Country) 

  • Research

    • Singapore (Country) 
• Research
• 

  Selected Grants

  • A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 52-week treatment period as an early intervention in patients with attenuated psychosis syndrom 2017 - 2021
  • Auditory Perception and Emotion Recognition in Young People at Risk for Psychosis awarded by National Institutes of Health 2016 - 2019
  • Study to Evaulate the Kappa Opioid Receptor as a Target for the Treatment of Mood and Anxiety Spectrum Disorders by Evaluating Whether LY2456302 Engages Reward-related Neural Circuitry. awarded by National Institutes of Health 2013 - 2017
  • Specific Auditory Perception Impairment and Emotion Recognition in Schizophrenia awarded by National Institutes of Health 2014 - 2017
  • FAST- MAS Administrative Task Year 3 awarded by National Institutes of Health 2014 - 2015
  • IPA - Richard Keefe 2013 - 2014
  • IPA - Richard Keefe awarded by Veterans Administration Medical Center 2012 - 2013
  • IPA - Richard Keefe awarded by Veterans Administration Medical Center 2010 - 2011
  • Neural Circuitry And Cognitive Function In Schizophrenia awarded by National Institutes of Health 1995 - 2001
  • Neural Circuitry & Cognitive Function In Schizophrenia awarded by National Institutes of Health 1995 - 1999
  • Neural Circuitry & Function In Schizophrenia awarded by National Institutes of Health 1995 - 1999
  • Neural Corcuitry And Cognitive Function In Schizophrenia awarded by National Institutes of Health 1995 - 1999
• 

  External Relationships

  • Boehringer Ingleheim
  • Karuna
  • WCG VeraSci
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Keefe, Richard S. E., Elena Cañadas, Deborah Farlow, and Amit Etkin. “Digital Intervention for Cognitive Deficits in Major Depression: A Randomized Controlled Trial to Assess Efficacy and Safety in Adults.” Am J Psychiatry 179, no. 7 (July 2022): 482–89. https://doi.org/10.1176/appi.ajp.21020125.
       Full Text  Link to Item
    • Zhang, Lusi, Scot Kristian Hill, Bin Guo, Baolin Wu, Ney Alliey-Rodriguez, Seenae Eum, Paulo Lizano, et al. “Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders.” Prog Neuropsychopharmacol Biol Psychiatry 113 (March 8, 2022): 110464. https://doi.org/10.1016/j.pnpbp.2021.110464.
       Full Text  Link to Item
    • Kraus, Michael S., Trina M. Walker, Diana Perkins, and Richard S. E. Keefe. “Basic auditory processing and emotion recognition in individuals at clinical high risk for psychosis.” Schizophr Res Cogn 27 (March 2022): 100225. https://doi.org/10.1016/j.scog.2021.100225.
       Full Text  Link to Item
    • Lim, Keane, Attilio Rapisarda, Richard S. E. Keefe, and Jimmy Lee. “Social skills, negative symptoms and real-world functioning in individuals at ultra-high risk of psychosis.” Asian J Psychiatr 69 (March 2022): 102996. https://doi.org/10.1016/j.ajp.2021.102996.
       Full Text  Link to Item
    • Eskridge, Courtney L. M., William C. Hochberger, Erin T. Kaseda, Rebekka Lencer, James L. Reilly, Sarah K. Keedy, Richard S. E. Keefe, et al. “Deficits in generalized cognitive ability, visual sensorimotor function, and inhibitory control represent discrete domains of neurobehavioral deficit in psychotic disorders.” Schizophr Res 236 (October 2021): 54–60. https://doi.org/10.1016/j.schres.2021.07.036.
       Full Text  Link to Item
    • Keefe, Richard S. E., Scott W. Woods, Tyrone D. Cannon, Stephan Ruhrmann, Daniel H. Mathalon, Philip McGuire, Holger Rosenbrock, et al. “A randomized Phase II trial evaluating efficacy, safety, and tolerability of oral BI 409306 in attenuated psychosis syndrome: Design and rationale.” Early Interv Psychiatry 15, no. 5 (October 2021): 1315–25. https://doi.org/10.1111/eip.13083.
       Full Text  Link to Item
    • Lim, Keane, Jason Smucny, Deanna M. Barch, Max Lam, Richard S. E. Keefe, and Jimmy Lee. “Cognitive Subtyping in Schizophrenia: A Latent Profile Analysis.” Schizophr Bull 47, no. 3 (April 29, 2021): 712–21. https://doi.org/10.1093/schbul/sbaa157.
       Full Text  Link to Item
    • Fleischhacker, W Wolfgang, Jana Podhorna, Martina Gröschl, Sanjay Hake, Yihua Zhao, Songqiao Huang, Richard S. E. Keefe, et al. “Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study.” Lancet Psychiatry 8, no. 3 (March 2021): 191–201. https://doi.org/10.1016/S2215-0366(20)30513-7.
       Full Text  Link to Item
    • Cohen, Elan A., Howard H. Hassman, Larry Ereshefsky, David P. Walling, Vera M. Grindell, Richard S. E. Keefe, Katarzyna Wyka, and William P. Horan. “Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders.” Neuropsychopharmacology 46, no. 4 (March 2021): 844–50. https://doi.org/10.1038/s41386-020-00911-5.
       Full Text  Link to Item
    • Keefe, Richard S. E. “Where do we cut the bell-shaped curve of CIAS?” Schizophr Res 228 (February 2021): 633–34. https://doi.org/10.1016/j.schres.2021.01.013.
       Full Text  Link to Item
    • Seccomandi, Benedetta, Deborah Agbedjro, Morris Bell, Richard S. E. Keefe, Matcheri Keshavan, Silvana Galderisi, Joanna Fiszdon, et al. “Exploring the role of age as a moderator of cognitive remediation for people with schizophrenia.” Schizophr Res 228 (February 2021): 29–35. https://doi.org/10.1016/j.schres.2020.11.060.
       Full Text  Link to Item
    • Seccomandi, Benedetta, Deborah Agbedjro, Morris Bell, Richard S. E. Keefe, Matcheri Keshavan, Silvana Galderisi, Joanna Fiszdon, et al. “Can IQ moderate the response to cognitive remediation in people with schizophrenia?” J Psychiatr Res 133 (January 2021): 38–45. https://doi.org/10.1016/j.jpsychires.2020.12.013.
       Full Text  Link to Item
    • Turner, Travis H., Alexandra Atkins, and Richard S. E. Keefe. “Virtual Reality Functional Capacity Assessment Tool (VRFCAT-SL) in Parkinson's Disease.” J Parkinsons Dis 11, no. 4 (2021): 1917–25. https://doi.org/10.3233/JPD-212688.
       Full Text  Link to Item
    • Keefe, Richard S. E., Michael F. Green, and Philip D. Harvey. “Requisite Skills and the Meaningful Measurement of Cognition.” Jama Psychiatry 77, no. 11 (November 1, 2020): 1103–4. https://doi.org/10.1001/jamapsychiatry.2020.1618.
       Full Text  Link to Item
    • Harvey, Philip D., William P. Horan, Alexandra S. Atkins, Heather Stevens, Matthew Welch, Joshua Yuan, Thomas L. Patterson, Meera Narasimhan, and Richard S. E. Keefe. “Factor structure of cognitive performance and functional capacity in schizophrenia: Evidence for differences across functional capacity measures.” Schizophr Res 223 (September 2020): 297–304. https://doi.org/10.1016/j.schres.2020.08.010.
       Full Text  Link to Item
    • Kilciksiz, C. M., R. Keefe, J. Benoit, D. Öngür, and J. Torous. “Verbal memory measurement towards digital perspectives in first-episode psychosis: A review.” Schizophrenia Research: Cognition 21 (September 1, 2020). https://doi.org/10.1016/j.scog.2020.100177.
       Full Text
    • Lindenmayer, Jean-Pierre, Abraham Goldring, Sophia Borne, Anzalee Khan, Richard S. E. Keefe, Beverly J. Insel, Amod Thanju, Isidora Ljuri, and Bronwen Foreman. “Assessing instrumental activities of daily living (iADL) with a game-based assessment for individuals with schizophrenia.” Schizophr Res 223 (September 2020): 166–72. https://doi.org/10.1016/j.schres.2020.07.001.
       Full Text  Link to Item
    • Chaturvedi, Rahul, Michael Kraus, and Richard S. E. Keefe. “A new measure of authentic auditory emotion recognition: Application to patients with schizophrenia.” Schizophr Res 222 (August 2020): 450–54. https://doi.org/10.1016/j.schres.2019.11.043.
       Full Text  Link to Item
    • Krystal, Andrew D., Diego A. Pizzagalli, Moria Smoski, Sanjay J. Mathew, John Nurnberger, Sarah H. Lisanby, Dan Iosifescu, et al. “A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia.” Nat Med 26, no. 5 (May 2020): 760–68. https://doi.org/10.1038/s41591-020-0806-7.
       Full Text  Link to Item
    • Ho, New Fei, Benjamin J. H. Lee, Jordon X. J. Tng, Max Z. Y. Lam, Guoyang Chen, Mingyuan Wang, Juan Zhou, Richard S. E. Keefe, and Kang Sim. “Corticolimbic brain anomalies are associated with cognitive subtypes in psychosis: A longitudinal study.” Eur Psychiatry 63, no. 1 (April 27, 2020): e40. https://doi.org/10.1192/j.eurpsy.2020.36.
       Full Text  Link to Item
    • Kollins, Scott H., Denton J. DeLoss, Elena Cañadas, Jacqueline Lutz, Robert L. Findling, Richard S. E. Keefe, Jeffery N. Epstein, Andrew J. Cutler, and Stephen V. Faraone. “A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial.” Lancet Digit Health 2, no. 4 (April 2020): e168–78. https://doi.org/10.1016/S2589-7500(20)30017-0.
       Full Text  Link to Item
    • Kraus, Michael S., James M. Gold, Deanna M. Barch, Trina M. Walker, Charlotte A. Chun, Robert W. Buchanan, John G. Csernansky, et al. “The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures.” Schizophr Res Cogn 19 (March 2020): 100161. https://doi.org/10.1016/j.scog.2019.100161.
       Full Text  Link to Item
    • Rakesh, Gopalkumar, Nicholas A. Mischel, Bruce Luber, Richard S. E. Keefe, Sara Emory, Sarah H. Lisanby, and Steven T. Szabo. “Theta Burst for Cognitive Remediation in Schizophrenia: A Case Series and Feasibility Study.” J Ect 36, no. 1 (March 2020): 72–74. https://doi.org/10.1097/YCT.0000000000000625.
       Full Text  Link to Item
    • Ventura, Joseph, Tamara Welikson, Arielle Ered, Kenneth L. Subotnik, Richard S. E. Keefe, Gerhard S. Hellemann, and Keith H. Nuechterlein. “Virtual reality assessment of functional capacity in the early course of schizophrenia: Associations with cognitive performance and daily functioning.” Early Interv Psychiatry 14, no. 1 (February 2020): 106–14. https://doi.org/10.1111/eip.12831.
       Full Text  Link to Item
    • Goldberg, T. E., P. D. Harvey, D. P. Devanand, R. S. E. Keefe, and J. J. Gomar. “Development of an UPSA Short Form for Use in Longitudinal Studies in the Early Alzheimer's Disease Spectrum.” J Prev Alzheimers Dis 7, no. 3 (2020): 179–83. https://doi.org/10.14283/jpad.2019.51.
       Full Text  Link to Item
    • Pani, Luca, and Richard S. E. Keefe. “Approaches to attenuated psychosis syndrome treatments: A perspective on the regulatory issues.” Schizophr Res Cogn 18 (December 2019): 100155. https://doi.org/10.1016/j.scog.2019.100155.
       Full Text  Link to Item
    • Harvey, Philip D., Anzalee Khan, Alexandra Atkins, Trina M. Walker, and Richard S. E. Keefe. “Comprehensive review of the research employing the schizophrenia cognition rating scale (SCoRS).” Schizophr Res 210 (August 2019): 30–38. https://doi.org/10.1016/j.schres.2019.05.040.
       Full Text  Link to Item
    • Harvey, Philip D., Anzalee Khan, Alexandra Atkins, and Richard Se Keefe. “Virtual reality assessment of functional capacity in people with Schizophrenia: Associations with reduced emotional experience and prediction of functional outcomes.” Psychiatry Res 277 (July 2019): 58–63. https://doi.org/10.1016/j.psychres.2019.01.045.
       Full Text  Link to Item
    • Keefe, Richard S. E. “Why are there no approved treatments for cognitive impairment in schizophrenia?” World Psychiatry 18, no. 2 (June 2019): 167–68. https://doi.org/10.1002/wps.20648.
       Full Text  Link to Item
    • Mahncke, Henry W., Sarah-Jane Kim, Annika Rose, Catherine Stasio, Peter Buckley, Stanley Caroff, Erica Duncan, et al. “Evaluation of a plasticity-based cognitive training program in schizophrenia: Results from the eCaesar trial.” Schizophr Res 208 (June 2019): 182–89. https://doi.org/10.1016/j.schres.2019.03.006.
       Full Text  Link to Item
    • Kraus, Michael S., Trina M. Walker, L Fredrik Jarskog, Robert A. Millet, and Richard S. E. Keefe. “Basic auditory processing deficits and their association with auditory emotion recognition in schizophrenia.” Schizophr Res 204 (February 2019): 155–61. https://doi.org/10.1016/j.schres.2018.08.031.
       Full Text  Link to Item
    • Krystal, Andrew D., Diego A. Pizzagalli, Sanjay J. Mathew, Gerard Sanacora, Richard Keefe, Allen Song, Joseph Calabrese, et al. “The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development.” Nat Rev Drug Discov 18, no. 1 (December 28, 2018): 82–84. https://doi.org/10.1038/nrd.2018.222.
       Full Text  Link to Item
    • Wang, Chenhao, Jimmy Lee, New Fei Ho, Joseph K. W. Lim, Joann S. Poh, Gurpreet Rekhi, Ranga Krishnan, et al. “Large-Scale Network Topology Reveals Heterogeneity in Individuals With at Risk Mental State for Psychosis: Findings From the Longitudinal Youth-at-Risk Study.” Cereb Cortex 28, no. 12 (December 1, 2018): 4234–43. https://doi.org/10.1093/cercor/bhx278.
       Full Text  Link to Item
    • Keefe, Richard S. E., and Luca Pani. “Take This Cognitive Training Efficacy Bar Fight Outside (to a Regulatory Agency).” Biol Psychiatry Cogn Neurosci Neuroimaging 3, no. 11 (November 2018): 900–902. https://doi.org/10.1016/j.bpsc.2018.09.002.
       Full Text  Link to Item
    • Yang, Zixu, Keane Lim, Max Lam, Richard Keefe, and Jimmy Lee. “Factor structure of the positive and negative syndrome scale (PANSS) in people at ultra high risk (UHR) for psychosis.” Schizophr Res 201 (November 2018): 85–90. https://doi.org/10.1016/j.schres.2018.05.024.
       Full Text  Link to Item
    • Lam, Max, Jimmy Lee, Attilio Rapisarda, Yuen Mei See, Zixu Yang, Sara-Ann Lee, Nur Amirah Abdul-Rashid, et al. “Longitudinal Cognitive Changes in Young Individuals at Ultrahigh Risk for Psychosis.” Jama Psychiatry 75, no. 9 (September 1, 2018): 929–39. https://doi.org/10.1001/jamapsychiatry.2018.1668.
       Full Text  Link to Item
    • Fava, Maurizio, Atul R. Mahableshwarkar, William Jacobson, Wei Zhong, Richard Se Keefe, Christina Kurre Olsen, and Judith Jaeger. “What is the overlap between subjective and objective cognitive impairments in MDD?” Ann Clin Psychiatry 30, no. 3 (August 2018): 176–84.
       Link to Item
    • Xavier, Rose Mary, Jennifer R. Dungan, Richard S. E. Keefe, and Allison Vorderstrasse. “Polygenic signal for symptom dimensions and cognitive performance in patients with chronic schizophrenia.” Schizophr Res Cogn 12 (June 2018): 11–19. https://doi.org/10.1016/j.scog.2018.01.001.
       Full Text  Link to Item
    • Keefe, Richard S. E., George Nomikos, Wei Zhong, Michael Cronquist Christensen, and William Jacobson. “A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction.” Int J Neuropsychopharmacol 21, no. 5 (May 1, 2018): 442–47. https://doi.org/10.1093/ijnp/pyy020.
       Full Text  Link to Item
    • Xavier, Rose Mary, Allison Vorderstrasse, Richard S. E. Keefe, and Jennifer R. Dungan. “Genetic correlates of insight in schizophrenia.” Schizophr Res 195 (May 2018): 290–97. https://doi.org/10.1016/j.schres.2017.10.021.
       Full Text  Link to Item
    • Blokland, Gabriëlla A. M., Elisabetta C. Del Re, Raquelle I. Mesholam-Gately, Jorge Jovicich, Joey W. Trampush, Matcheri S. Keshavan, Lynn E. DeLisi, et al. “The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS) consortium: A collaborative cognitive and neuroimaging genetics project.” Schizophr Res 195 (May 2018): 306–17. https://doi.org/10.1016/j.schres.2017.09.024.
       Full Text  Link to Item
    • Shafee, Rebecca, Pranav Nanda, Jaya L. Padmanabhan, Neeraj Tandon, Ney Alliey-Rodriguez, Sreeja Kalapurakkel, Daniel J. Weiner, et al. “Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls.” Transl Psychiatry 8, no. 1 (April 12, 2018): 78. https://doi.org/10.1038/s41398-018-0124-8.
       Full Text  Link to Item
    • Kendler, K. S., H. Ohlsson, R. S. E. Keefe, K. Sundquist, and J. Sundquist. “The joint impact of cognitive performance in adolescence and familial cognitive aptitude on risk for major psychiatric disorders: a delineation of four potential pathways to illness.” Mol Psychiatry 23, no. 4 (April 2018): 1076–83. https://doi.org/10.1038/mp.2017.78.
       Full Text  Link to Item
    • Xavier, Rose Mary, Wei Pan, Jennifer R. Dungan, Richard S. E. Keefe, and Allison Vorderstrasse. “Unraveling interrelationships among psychopathology symptoms, cognitive domains and insight dimensions in chronic schizophrenia.” Schizophr Res 193 (March 2018): 83–90. https://doi.org/10.1016/j.schres.2017.07.002.
       Full Text  Link to Item
    • Healey, Kristin M., David L. Penn, Diana Perkins, Scott W. Woods, Richard S. E. Keefe, and Jean Addington. “Latent Profile Analysis and Conversion to Psychosis: Characterizing Subgroups to Enhance Risk Prediction.” Schizophr Bull 44, no. 2 (February 15, 2018): 286–96. https://doi.org/10.1093/schbul/sbx080.
       Full Text  Link to Item
    • Hochberger, W. C., T. Combs, J. L. Reilly, J. R. Bishop, R. S. E. Keefe, B. A. Clementz, M. S. Keshavan, et al. “Deviation from expected cognitive ability across psychotic disorders.” Schizophr Res 192 (February 2018): 300–307. https://doi.org/10.1016/j.schres.2017.05.019.
       Full Text  Link to Item
    • Atkins, A. S., A. Khan, D. Ulshen, A. Vaughan, D. Balentin, H. Dickerson, L. E. Liharska, B. Plassman, K. Welsh-Bohmer, and R. S. E. Keefe. “Assessment of Instrumental Activities of Daily Living in Older Adults with Subjective Cognitive Decline Using the Virtual Reality Functional Capacity Assessment Tool (VRFCAT).” J Prev Alzheimers Dis 5, no. 4 (2018): 216–34. https://doi.org/10.14283/jpad.2018.28.
       Full Text  Link to Item
    • Romero, Heather R., Andreas U. Monsch, Kathleen M. Hayden, Brenda L. Plassman, Alexandra S. Atkins, Richard S. E. Keefe, Shyama Brewster, et al. “TOMMORROW neuropsychological battery: German language validation and normative study.” Alzheimers Dement (N Y) 4 (2018): 314–23. https://doi.org/10.1016/j.trci.2018.06.009.
       Full Text  Link to Item
    • Harvey, Philip D., Anzalee Khan, and Richard S. E. Keefe. “Using the Positive and Negative Syndrome Scale (PANSS) to Define Different Domains of Negative Symptoms: Prediction of Everyday Functioning by Impairments in Emotional Expression and Emotional Experience.” Innov Clin Neurosci 14, no. 11–12 (December 1, 2017): 18–22.
       Link to Item
    • Khan, Anzalee, Lora Liharska, Philip D. Harvey, Alexandra Atkins, Daniel Ulshen, and Richard S. E. Keefe. “Negative Symptom Dimensions of the Positive and Negative Syndrome Scale Across Geographical Regions: Implications for Social, Linguistic, and Cultural Consistency.” Innov Clin Neurosci 14, no. 11–12 (December 1, 2017): 30–40.
       Link to Item
    • Ang, Mei San, Nur Amirah Abdul Rashid, Max Lam, Attilio Rapisarda, Michael Kraus, Richard S. E. Keefe, and Jimmy Lee. “The Impact of Medication Anticholinergic Burden on Cognitive Performance in People With Schizophrenia.” J Clin Psychopharmacol 37, no. 6 (December 2017): 651–56. https://doi.org/10.1097/JCP.0000000000000790.
       Full Text  Link to Item
    • Georgiades, Anastasia, Vicki G. Davis, Alexandra S. Atkins, Anzalee Khan, Trina W. Walker, Antony Loebel, George Haig, et al. “Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients.” Schizophr Res 190 (December 2017): 172–79. https://doi.org/10.1016/j.schres.2017.03.040.
       Full Text  Link to Item
    • Lam, Max, Mingyuan Wang, Wanping Huang, Goi Khia Eng, Attilio Rapisarda, Michael Kraus, Sim Kang, R. S. E. Keefe, and Jimmy Lee. “Establishing the Brief Assessment of Cognition - Short form.” J Psychiatr Res 93 (October 2017): 1–11. https://doi.org/10.1016/j.jpsychires.2017.05.006.
       Full Text  Link to Item
    • Cella, M., D. Stahl, S. Morris, R. S. E. Keefe, M. D. Bell, and T. Wykes. “Effects of cognitive remediation on negative symptoms dimensions: exploring the role of working memory.” Psychol Med, September 4, 2017, 1–9. https://doi.org/10.1017/S0033291717000757.
       Full Text  Link to Item
    • Keefe, Richard S. E., Vicki G. Davis, Philip D. Harvey, Alexandra S. Atkins, George M. Haig, Owen Hagino, Stephen Marder, Dana C. Hilt, and Daniel Umbricht. “Placebo Response and Practice Effects in Schizophrenia Cognition Trials.” Jama Psychiatry 74, no. 8 (August 1, 2017): 807–14. https://doi.org/10.1001/jamapsychiatry.2017.1574.
       Full Text  Link to Item
    • Mazhari, Shahrzad, Ali R. Ghafaree-Nejad, Somayeh Soleymani-Zade, and Richard S. E. Keefe. “Validation of the Persian version of the Schizophrenia Cognition Rating Scale (SCoRS) in patients with schizophrenia.” Asian J Psychiatr 27 (June 2017): 12–15. https://doi.org/10.1016/j.ajp.2017.02.007.
       Full Text  Link to Item
    • Keefe, Richard S. E., and René S. Kahn. “Cognitive Decline and Disrupted Cognitive Trajectory in Schizophrenia.” Jama Psychiatry 74, no. 5 (May 1, 2017): 535–36. https://doi.org/10.1001/jamapsychiatry.2017.0312.
       Full Text  Link to Item
    • Reilly, James L., S Kristian Hill, James M. Gold, Richard S. E. Keefe, Brett A. Clementz, Elliot Gershon, Matcheri S. Keshavan, Godfrey Pearlson, Carol A. Tamminga, and John A. Sweeney. “Impaired Context Processing is Attributable to Global Neuropsychological Impairment in Schizophrenia and Psychotic Bipolar Disorder.” Schizophr Bull 43, no. 2 (March 1, 2017): 397–406. https://doi.org/10.1093/schbul/sbw081.
       Full Text  Link to Item
    • Atkins, Alexandra S., Tina Tseng, Adam Vaughan, Elizabeth W. Twamley, Philip Harvey, Thomas Patterson, Meera Narasimhan, and Richard S. E. Keefe. “Validation of the tablet-administered Brief Assessment of Cognition (BAC App).” Schizophr Res 181 (March 2017): 100–106. https://doi.org/10.1016/j.schres.2016.10.010.
       Full Text  Link to Item
    • Addington, Jean, Lu Liu, Diana O. Perkins, Ricardo E. Carrion, Richard S. E. Keefe, and Scott W. Woods. “The Role of Cognition and Social Functioning as Predictors in the Transition to Psychosis for Youth With Attenuated Psychotic Symptoms.” Schizophr Bull 43, no. 1 (January 2017): 57–63. https://doi.org/10.1093/schbul/sbw152.
       Full Text  Link to Item
    • Kraus, Michael, Attilio Rapisarda, Max Lam, Jamie Y. J. Thong, Jimmy Lee, Mythily Subramaniam, Simon L. Collinson, Siow Ann Chong, and Richard S. E. Keefe. “Disrupted latent inhibition in individuals at ultra high-risk for developing psychosis.” Schizophr Res Cogn 6 (December 2016): 1–8. https://doi.org/10.1016/j.scog.2016.07.003.
       Full Text  Link to Item
    • Mahableshwarkar, Atul R., John Zajecka, William Jacobson, Yinzhong Chen, and Richard Se Keefe. “A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.” Neuropsychopharmacology 41, no. 12 (November 2016): 2961. https://doi.org/10.1038/npp.2016.181.
       Full Text  Link to Item
    • Kantrowitz, Joshua T., Alice Medalia, Richard S. E. Keefe, Philip D. Harvey, Gerard Bruder, Deanna M. Barch, Tse Choo, Seonjoo Lee, and Jeffrey A. Lieberman. “Dr Kantrowitz and Colleagues Reply.” J Clin Psychiatry 77, no. 10 (October 2016): e1353. https://doi.org/10.4088/JCP.16lr10887a.
       Full Text  Link to Item
    • Wang, C., F. Ji, Z. Hong, J. S. Poh, R. Krishnan, J. Lee, G. Rekhi, et al. “Disrupted salience network functional connectivity and white-matter microstructure in persons at risk for psychosis: findings from the LYRIKS study.” Psychol Med 46, no. 13 (October 2016): 2771–83. https://doi.org/10.1017/S0033291716001410.
       Full Text  Link to Item
    • Keefe, Richard S. E., Vicki G. Davis, Alexandra S. Atkins, Adam Vaughan, Tom Patterson, Meera Narasimhan, and Philip D. Harvey. “Validation of a Computerized test of Functional Capacity.” Schizophr Res 175, no. 1–3 (August 2016): 90–96. https://doi.org/10.1016/j.schres.2016.03.038.
       Full Text  Link to Item
    • Cruz, Breno F., Camilo B de Resende, Carolina F. Carvalhaes, Clareci S. Cardoso, Antonio L. Teixeira, Richard S. Keefe, Fábio L. Rocha, and João V. Salgado. “Interview-based assessment of cognition is a strong predictor of quality of life in patients with schizophrenia and severe negative symptoms.” Braz J Psychiatry 38, no. 3 (July 2016): 216–21. https://doi.org/10.1590/1516-4446-2015-1776.
       Full Text  Link to Item
    • Lim, J., S. -. A. Lee, M. Lam, A. Rapisarda, M. Kraus, R. S. E. Keefe, and J. Lee. “The relationship between negative symptom subdomains and cognition.” Psychol Med 46, no. 10 (July 2016): 2169–77. https://doi.org/10.1017/S0033291716000726.
       Full Text  Link to Item
    • Kantrowitz, Joshua T., Zafar Sharif, Alice Medalia, Richard S. E. Keefe, Philip Harvey, Gerard Bruder, Deanna M. Barch, Tse Choo, Seonjoo Lee, and Jeffrey A. Lieberman. “A Multicenter, Rater-Blinded, Randomized Controlled Study of Auditory Processing-Focused Cognitive Remediation Combined With Open-Label Lurasidone in Patients With Schizophrenia and Schizoaffective Disorder.” J Clin Psychiatry 77, no. 6 (June 2016): 799–806. https://doi.org/10.4088/JCP.15m09998.
       Full Text  Link to Item
    • Keefe, Richard S. E. “Treating cognitive impairment in depression: an unmet need.” Lancet Psychiatry 3, no. 5 (May 2016): 392–93. https://doi.org/10.1016/S2215-0366(16)00095-X.
       Full Text  Link to Item
    • Keefe, Richard S. E., and Abraham Reichenberg. “Predicting Schizophrenia.” Jama Psychiatry 73, no. 5 (May 1, 2016): 441–42. https://doi.org/10.1001/jamapsychiatry.2016.0138.
       Full Text  Link to Item
    • McCleery, A., M. F. Green, G. S. Hellemann, L. E. Baade, J. M. Gold, R. S. E. Keefe, R. S. Kern, et al. “Latent structure of cognition in schizophrenia: a confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB).” Psychol Med 46, no. 5 (April 2016): 1119. https://doi.org/10.1017/S0033291715002433.
       Full Text  Link to Item
    • Walling, David, Stephen R. Marder, John Kane, W Wolfgang Fleischhacker, Richard S. E. Keefe, David A. Hosford, Chris Dvergsten, et al. “Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia.” Schizophr Bull 42, no. 2 (March 2016): 335–43. https://doi.org/10.1093/schbul/sbv072.
       Full Text  Link to Item
    • Keefe, Richard S. E., George M. Haig, Stephen R. Marder, Philip D. Harvey, Eduardo Dunayevich, Alice Medalia, Michael Davidson, et al. “Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia.” Schizophr Bull 42, no. 1 (January 2016): 19–33. https://doi.org/10.1093/schbul/sbv111.
       Full Text  Link to Item
    • Hochberger, W. C., S. K. Hill, C. L. M. Nelson, J. L. Reilly, R. S. E. Keefe, G. D. Pearlson, M. S. Keshavan, C. A. Tamminga, B. A. Clementz, and J. A. Sweeney. “Unitary construct of generalized cognitive ability underlying BACS performance across psychotic disorders and in their first-degree relatives.” Schizophr Res 170, no. 1 (January 2016): 156–61. https://doi.org/10.1016/j.schres.2015.11.022.
       Full Text  Link to Item
    • Keefe, Richard S. E., Herbert A. Meltzer, Nancy Dgetluck, Maria Gawryl, Gerhard Koenig, Hans J. Moebius, Ilise Lombardo, and Dana C. Hilt. “Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.” Neuropsychopharmacology 40, no. 13 (December 2015): 3053–60. https://doi.org/10.1038/npp.2015.176.
       Full Text  Link to Item
    • Keefe, Richard S. E., and Philip D. Harvey. “Understanding symbol coding in schizophrenia.” Biol Psychiatry 78, no. 11 (December 1, 2015): 744–46. https://doi.org/10.1016/j.biopsych.2015.09.005.
       Full Text  Link to Item
    • Klauser, Paul, Juan Zhou, Joseph K. W. Lim, Joann S. Poh, Hui Zheng, Han Ying Tng, Ranga Krishnan, et al. “Lack of Evidence for Regional Brain Volume or Cortical Thickness Abnormalities in Youths at Clinical High Risk for Psychosis: Findings From the Longitudinal Youth at Risk Study.” Schizophr Bull 41, no. 6 (November 2015): 1285–93. https://doi.org/10.1093/schbul/sbv012.
       Full Text  Link to Item
    • Iwata, Y., S. Nakajima, T. Suzuki, R. S. E. Keefe, E. Plitman, J. K. Chung, F. Caravaggio, M. Mimura, A. Graff-Guerrero, and H. Uchida. “Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials.” Mol Psychiatry 20, no. 10 (October 2015): 1151–60. https://doi.org/10.1038/mp.2015.68.
       Full Text  Link to Item
    • Kelly, Deanna L., Kelli M. Sullivan, Joseph P. McEvoy, Robert P. McMahon, Heidi J. Wehring, James M. Gold, Fang Liu, et al. “Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms.” J Clin Psychopharmacol 35, no. 4 (August 2015): 374–81. https://doi.org/10.1097/JCP.0000000000000345.
       Full Text  Link to Item
    • Kristian Hill, S., Alison Buchholz, Hayley Amsbaugh, James L. Reilly, Leah H. Rubin, James M. Gold, Richard S. E. Keefe, et al. “Working memory impairment in probands with schizoaffective disorder and first degree relatives of schizophrenia probands extend beyond deficits predicted by generalized neuropsychological impairment.” Schizophr Res 166, no. 1–3 (August 2015): 310–15. https://doi.org/10.1016/j.schres.2015.05.018.
       Full Text  Link to Item
    • Kaneda, Y., and R. S. E. Keefe. “An abbreviated version of the brief assessment of cognition in schizophrenia (BACS).” European Journal of Psychiatry 29, no. 2 (July 30, 2015): 131–34. https://doi.org/10.4321/s0213-61632015000200004.
       Full Text
    • Hill, S Kristian, James L. Reilly, Michael E. Ragozzino, Leah H. Rubin, Jeffrey R. Bishop, Ruben C. Gur, Elliot S. Gershon, et al. “Regressing to Prior Response Preference After Set Switching Implicates Striatal Dysfunction Across Psychotic Disorders: Findings From the B-SNIP Study.” Schizophr Bull 41, no. 4 (July 2015): 940–50. https://doi.org/10.1093/schbul/sbu130.
       Full Text  Link to Item
    • Mahableshwarkar, Atul R., John Zajecka, William Jacobson, Yinzhong Chen, and Richard S. E. Keefe. “A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.” Neuropsychopharmacology 40, no. 8 (July 2015): 2025–37. https://doi.org/10.1038/npp.2015.52.
       Full Text  Link to Item
    • Atkins, A. S., I. Stroescu, N. B. Spagnola, V. G. Davis, T. D. Patterson, M. Narasimhan, P. D. Harvey, and R. S. E. Keefe. “Assessment of Age-Related Differences in Functional Capacity Using the Virtual Reality Functional Capacity Assessment Tool (VRFCAT).” J Prev Alzheimers Dis 2, no. 2 (June 2015): 121–27. https://doi.org/10.14283/jpad.2015.61.
       Full Text  Link to Item
    • Jarskog, L Fredrik, Martin T. Lowy, Richard A. Grove, Richard S. E. Keefe, Joseph P. Horrigan, M Patricia Ball, Alan Breier, et al. “A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy.” Schizophr Res 164, no. 1–3 (May 2015): 136–42. https://doi.org/10.1016/j.schres.2015.01.041.
       Full Text  Link to Item
    • Lim, Jeanette, Gurpreet Rekhi, Attilio Rapisarda, Max Lam, Michael Kraus, Richard S. E. Keefe, and Jimmy Lee. “Impact of psychiatric comorbidity in individuals at Ultra High Risk of psychosis - Findings from the Longitudinal Youth at Risk Study (LYRIKS).” Schizophr Res 164, no. 1–3 (May 2015): 8–14. https://doi.org/10.1016/j.schres.2015.03.007.
       Full Text  Link to Item
    • Araújo, Geovany Eliberto, Camilo Brandão de Resende, Ana Cecília Alves Cardoso, Antonio Lúcio Teixeira, Richard S. E. Keefe, and João Vinícius Salgado. “Validity and reliability of the Brazilian Portuguese version of the BACS (Brief Assessment of Cognition in Schizophrenia).” Clinics (Sao Paulo) 70, no. 4 (April 2015): 278–82. https://doi.org/10.6061/clinics/2015(04)10.
       Full Text  Link to Item
    • Bauer, Isabelle E., Austin Ouyang, Benson Mwangi, Marsal Sanches, Giovana B. Zunta-Soares, Richard S. E. Keefe, Hao Huang, and Jair C. Soares. “Reduced white matter integrity and verbal fluency impairment in young adults with bipolar disorder: a diffusion tensor imaging study.” J Psychiatr Res 62 (March 2015): 115–22. https://doi.org/10.1016/j.jpsychires.2015.01.008.
       Full Text  Link to Item
    • Keefe, Richard S. E., Vicki G. Davis, Nathan B. Spagnola, Dana Hilt, Nancy Dgetluck, Stacy Ruse, Thomas D. Patterson, Meera Narasimhan, and Philip D. Harvey. “Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale.” Eur Neuropsychopharmacol 25, no. 2 (February 2015): 176–84. https://doi.org/10.1016/j.euroneuro.2014.06.009.
       Full Text  Link to Item
    • Bauer, Isabelle E., Richard S. E. Keefe, Marsal Sanches, Robert Suchting, Charles E. Green, and Jair C. Soares. “Evaluation of cognitive function in bipolar disorder using the Brief Assessment of Cognition in Affective Disorders (BAC-A).” J Psychiatr Res 60 (January 2015): 81–86. https://doi.org/10.1016/j.jpsychires.2014.10.002.
       Full Text  Link to Item
    • Harvey, Philip D., and Richard S. E. Keefe. “Methods for delivering and evaluating the efficacy of cognitive enhancement.” Handb Exp Pharmacol 228 (2015): 5–25. https://doi.org/10.1007/978-3-319-16522-6_1.
       Full Text  Link to Item
    • Healey, Kristin M., Dennis R. Combs, Clare M. Gibson, Richard S. E. Keefe, David L. Roberts, and David L. Penn. “Observable Social Cognition--A Rating Scale: an interview-based assessment for schizophrenia.” Cogn Neuropsychiatry 20, no. 3 (2015): 198–221. https://doi.org/10.1080/13546805.2014.999915.
       Full Text  Link to Item
    • Lui, S., L. Yao, Y. Xiao, S. K. Keedy, J. L. Reilly, R. S. Keefe, C. A. Tamminga, et al. “Resting-state brain function in schizophrenia and psychotic bipolar probands and their first-degree relatives.” Psychol Med 45, no. 1 (January 2015): 97–108. https://doi.org/10.1017/S003329171400110X.
       Full Text  Link to Item
    • McCleery, A., M. F. Green, G. S. Hellemann, L. E. Baade, J. M. Gold, R. S. E. Keefe, R. S. Kern, et al. “Latent structure of cognition in schizophrenia: a confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB).” Psychol Med 45, no. 12 (2015): 2657–66. https://doi.org/10.1017/S0033291715000641.
       Full Text  Link to Item
    • Lam, M., S. L. Collinson, G. K. Eng, A. Rapisarda, M. Kraus, J. Lee, S. A. Chong, and R. S. E. Keefe. “Refining the latent structure of neuropsychological performance in schizophrenia.” Psychol Med 44, no. 16 (December 2014): 3557–70. https://doi.org/10.1017/S0033291714001020.
       Full Text  Link to Item
    • Ethridge, Lauren E., Melanie Soilleux, Paul A. Nakonezny, James L. Reilly, S Kristian Hill, Richard S. E. Keefe, Elliot S. Gershon, et al. “Behavioral response inhibition in psychotic disorders: diagnostic specificity, familiality and relation to generalized cognitive deficit.” Schizophr Res 159, no. 2–3 (November 2014): 491–98. https://doi.org/10.1016/j.schres.2014.08.025.
       Full Text  Link to Item
    • Gray, Bradley E., Robert P. McMahon, Michael F. Green, Larry J. Seidman, Raquelle I. Mesholam-Gately, Robert S. Kern, Keith H. Nuechterlein, Richard S. Keefe, and James M. Gold. “Detecting reliable cognitive change in individual patients with the MATRICS Consensus Cognitive Battery.” Schizophr Res 159, no. 1 (October 2014): 182–87. https://doi.org/10.1016/j.schres.2014.07.032.
       Full Text  Link to Item
    • Hufford, Michael R., Vicki G. Davis, Dana Hilt, Nancy Dgetluck, Yona Geffen, Antony Loebel, George Haig, Luca Santarelli, and Richard S. E. Keefe. “Circadian rhythms in cognitive functioning among patients with schizophrenia: impact on signal detection in clinical trials of potential pro-cognitive therapies.” Schizophr Res 159, no. 1 (October 2014): 205–10. https://doi.org/10.1016/j.schres.2014.07.018.
       Full Text  Link to Item
    • Keefe, Richard S. E. “Cognition and motivation as treatment targets in schizophrenia.” Jama Psychiatry 71, no. 9 (September 2014): 987–88. https://doi.org/10.1001/jamapsychiatry.2014.1281.
       Full Text  Link to Item
    • Stout, Julie C., Sarah Queller, Kalyca N. Baker, Sean Cowlishaw, Cristina Sampaio, Cheryl Fitzer-Attas, Beth Borowsky, and Beth HD-CAB Investigators. “HD-CAB: a cognitive assessment battery for clinical trials in Huntington's disease 1,2,3.” Mov Disord 29, no. 10 (September 2014): 1281–88. https://doi.org/10.1002/mds.25964.
       Full Text  Link to Item
    • Keefe, Richard S. E., Kolleen H. Fox, Vicki G. Davis, Courtney Kennel, Trina M. Walker, Katherine E. Burdick, and Philip D. Harvey. “The Brief Assessment of Cognition In Affective Disorders (BAC-A):performance of patients with bipolar depression and healthy controls.” J Affect Disord 166 (September 2014): 86–92. https://doi.org/10.1016/j.jad.2014.05.002.
       Full Text  Link to Item
    • Marx, Christine E., Jimmy Lee, Mythily Subramaniam, Attilio Rapisarda, Dianne C. T. Bautista, Edwin Chan, Jason D. Kilts, et al. “Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia.” Psychopharmacology (Berl) 231, no. 17 (September 2014): 3647–62. https://doi.org/10.1007/s00213-014-3673-4.
       Full Text  Link to Item
    • Reilly, James L., Kyle Frankovich, Scot Hill, Elliot S. Gershon, Richard S. E. Keefe, Matcheri S. Keshavan, Godfrey D. Pearlson, Carol A. Tamminga, and John A. Sweeney. “Elevated antisaccade error rate as an intermediate phenotype for psychosis across diagnostic categories.” Schizophr Bull 40, no. 5 (September 2014): 1011–21. https://doi.org/10.1093/schbul/sbt132.
       Full Text  Link to Item
    • Yong, Emma, Mariapaola Barbato, David L. Penn, Richard S. E. Keefe, Scott W. Woods, Diana O. Perkins, and Jean Addington. “Exploratory analysis of social cognition and neurocognition in individuals at clinical high risk for psychosis.” Psychiatry Res 218, no. 1–2 (August 15, 2014): 39–43. https://doi.org/10.1016/j.psychres.2014.04.003.
       Full Text  Link to Item
    • Keefe, Richard S. E., Shawn M. McClintock, Robert M. Roth, P Murali Doraiswamy, Steven Tiger, and Manisha Madhoo. “Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review.” J Clin Psychiatry 75, no. 8 (August 2014): 864–76. https://doi.org/10.4088/JCP.13r08609.
       Full Text  Link to Item
    • Dandash, Orwa, Alex Fornito, Jimmy Lee, Richard S. E. Keefe, Michael W. L. Chee, R Alison Adcock, Christos Pantelis, Stephen J. Wood, and Ben J. Harrison. “Altered striatal functional connectivity in subjects with an at-risk mental state for psychosis.” Schizophr Bull 40, no. 4 (July 2014): 904–13. https://doi.org/10.1093/schbul/sbt093.
       Full Text  Link to Item
    • Rapisarda, Attilio, Michael Kraus, Yi Wen Tan, Max Lam, Goi Khia Eng, Jimmy Lee, Mythily Subramaniam, Simon L. Collinson, Siow Ann Chong, and Richard S. E. Keefe. “The continuous performance test, identical pairs: norms, reliability and performance in healthy controls and patients with schizophrenia in Singapore.” Schizophr Res 156, no. 2–3 (July 2014): 233–40. https://doi.org/10.1016/j.schres.2014.04.016.
       Full Text  Link to Item
    • Umbricht, Daniel, Richard S. E. Keefe, Stephen Murray, David A. Lowe, Richard Porter, George Garibaldi, and Luca Santarelli. “A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia.” Neuropsychopharmacology 39, no. 7 (June 2014): 1568–77. https://doi.org/10.1038/npp.2014.17.
       Full Text  Link to Item
    • Madhoo, Manisha, Richard S. E. Keefe, Robert M. Roth, Angelo Sambunaris, James Wu, Madhukar H. Trivedi, Colleen S. Anderson, and Robert Lasser. “Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder.” Neuropsychopharmacology 39, no. 6 (May 2014): 1388–98. https://doi.org/10.1038/npp.2013.334.
       Full Text  Link to Item
    • Ruse, Stacy A., Vicki G. Davis, Alexandra S. Atkins, K Ranga R. Krishnan, Kolleen H. Fox, Philip D. Harvey, and Richard S. E. Keefe. “Development of a virtual reality assessment of everyday living skills.” J Vis Exp, no. 86 (April 23, 2014). https://doi.org/10.3791/51405.
       Full Text  Link to Item
    • Ruse, Stacy A., Philip D. Harvey, Vicki G. Davis, Alexandra S. Atkins, Kolleen H. Fox, and Richard S. E. Keefe. “Virtual Reality Functional Capacity Assessment In Schizophrenia: Preliminary Data Regarding Feasibility and Correlations with Cognitive and Functional Capacity Performance.” Schizophr Res Cogn 1, no. 1 (March 2014): e21–26. https://doi.org/10.1016/j.scog.2014.01.004.
       Full Text  Link to Item
    • Mazhari, Shahrzad, Nooshin Parvaresh, Mahin Eslami Shahrbabaki, Mohammad M. Sadeghi, Nouzar Nakhaee, and Richard S. E. Keefe. “Validation of the Persian version of the brief assessment of cognition in schizophrenia in patients with schizophrenia and healthy controls.” Psychiatry Clin Neurosci 68, no. 2 (February 2014): 160–66. https://doi.org/10.1111/pcn.12107.
       Full Text  Link to Item
    • Keefe, Richard S. E. “The longitudinal course of cognitive impairment in schizophrenia: an examination of data from premorbid through posttreatment phases of illness.” J Clin Psychiatry 75 Suppl 2 (2014): 8–13. https://doi.org/10.4088/JCP.13065su1.02.
       Full Text  Link to Item
    • Meier, Madeline H., Avshalom Caspi, Abraham Reichenberg, Richard S. E. Keefe, Helen L. Fisher, HonaLee Harrington, Renate Houts, Richie Poulton, and Terrie E. Moffitt. “Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal study.” Am J Psychiatry 171, no. 1 (January 2014): 91–101. https://doi.org/10.1176/appi.ajp.2013.12111438.
       Full Text  Link to Item
    • Ruse, S. A., V. G. Davis, A. S. Atkins, K. R. R. Krishnan, K. H. Fox, P. D. Harvey, and R. S. E. Keefe. “Development of a virtual reality assessment of everyday living skills.” Journal of Visualized Experiments : Jove, no. 86 (2014). https://doi.org/10.3791/51405.
       Full Text
    • Meier, Madeline H., Idan Shalev, Terrie E. Moffitt, Shitij Kapur, Richard S. E. Keefe, Tien Y. Wong, Daniel W. Belsky, et al. “Microvascular abnormality in schizophrenia as shown by retinal imaging.” Am J Psychiatry 170, no. 12 (December 2013): 1451–59. https://doi.org/10.1176/appi.ajp.2013.13020234.
       Full Text  Link to Item
    • Rashid, Nur Amirah Abdul, Jeanette Lim, Max Lam, Siow-Ann Chong, Richard S. E. Keefe, and Jimmy Lee. “Unraveling the relationship between obesity, schizophrenia and cognition.” Schizophr Res 151, no. 1–3 (December 2013): 107–12. https://doi.org/10.1016/j.schres.2013.09.020.
       Full Text  Link to Item
    • Eng, Goi Khia, Max Lam, Yioe Ling Bong, Mythily Subramaniam, Dianne Bautista, Attilio Rapisarda, Michael Kraus, et al. “Brief assessment of cognition in schizophrenia: normative data in an English-speaking ethnic Chinese sample.” Arch Clin Neuropsychol 28, no. 8 (December 2013): 845–58. https://doi.org/10.1093/arclin/act060.
       Full Text  Link to Item
    • Lee, Jimmy, Gurpreet Rekhi, Natasha Mitter, Yioe Ling Bong, Michael S. Kraus, Max Lam, Attilio Rapisarda, et al. “The Longitudinal Youth at Risk Study (LYRIKS)--an Asian UHR perspective.” Schizophr Res 151, no. 1–3 (December 2013): 279–83. https://doi.org/10.1016/j.schres.2013.09.025.
       Full Text  Link to Item
    • Marder, Stephen R., Larry Alphs, Ion-George Anghelescu, Celso Arango, Thomas R. E. Barnes, Ivo Caers, David G. Daniel, et al. “Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia.” Schizophr Res 150, no. 2–3 (November 2013): 328–33. https://doi.org/10.1016/j.schres.2013.07.058.
       Full Text  Link to Item
    • Yaakub, Siti N., Kavitha Dorairaj, Joann S. Poh, Christopher L. Asplund, Ranga Krishnan, Jimmy Lee, Richard S. E. Keefe, R Alison Adcock, Stephen J. Wood, and Michael W. L. Chee. “Preserved working memory and altered brain activation in persons at risk for psychosis.” Am J Psychiatry 170, no. 11 (November 2013): 1297–1307. https://doi.org/10.1176/appi.ajp.2013.12081135.
       Full Text  Link to Item
    • Barbato, Mariapaola, Lu Liu, David L. Penn, Richard S. E. Keefe, Diana O. Perkins, Scott W. Woods, and Jean Addington. “Social cognition as a mediator between neurocognition and functional outcome in individuals at clinical high risk for psychosis.” Schizophr Res 150, no. 2–3 (November 2013): 542–46. https://doi.org/10.1016/j.schres.2013.08.015.
       Full Text  Link to Item
    • Hill, S Kristian, James L. Reilly, Richard S. E. Keefe, James M. Gold, Jeffrey R. Bishop, Elliot S. Gershon, Carol A. Tamminga, Godfrey D. Pearlson, Matcheri S. Keshavan, and John A. Sweeney. “Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study.” Am J Psychiatry 170, no. 11 (November 2013): 1275–84. https://doi.org/10.1176/appi.ajp.2013.12101298.
       Full Text  Link to Item
    • Kahn, René S., and Richard S. E. Keefe. “Schizophrenia is a cognitive illness: time for a change in focus.” Jama Psychiatry 70, no. 10 (October 2013): 1107–12. https://doi.org/10.1001/jamapsychiatry.2013.155.
       Full Text  Link to Item
    • Nutt, David, Christine C. Gispen-de Wied, Celso Arango, Richard S. E. Keefe, Rafael Penadés, Declan G. Murphy, Trevor W. Robbins, and Barbara J. Sahakian. “Cognition in schizophrenia: summary Nice Consultation Meeting 2012.” Eur Neuropsychopharmacol 23, no. 8 (August 2013): 769–78. https://doi.org/10.1016/j.euroneuro.2013.03.005.
       Full Text  Link to Item
    • Jarskog, L Fredrik, Zhengchao Dong, Alayar Kangarlu, Tiziano Colibazzi, Ragy R. Girgis, Lawrence S. Kegeles, Deanna M. Barch, et al. “Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.” Neuropsychopharmacology 38, no. 7 (June 2013): 1245–52. https://doi.org/10.1038/npp.2013.23.
       Full Text  Link to Item
    • Cruz, Breno Fiúza, Camilo Brandão de Resende, Mery Natali Abreu, Fábio Lopes Rocha, Antonio Lúcio Teixeira, Richard S. E. Keefe, and João Vinícius Salgado. “How specific are negative symptoms and cognitive impairment in schizophrenia? An analysis of PANSS and SCoRS.” Cogn Neuropsychiatry 18, no. 3 (May 2013): 243–51. https://doi.org/10.1080/13546805.2012.730995.
       Full Text  Link to Item
    • Keefe, R. S. E., H. C. Kraemer, R. S. Epstein, E. Frank, G. Haynes, T. P. Laughren, J. McNulty, S. D. Reed, J. Sanchez, and A. C. Leon. “Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials.” Innovations in Clinical Neuroscience 10, no. 5–6 (May 1, 2013).
    • Keefe, Richard S. E., Helena C. Kraemer, Robert S. Epstein, Ellen Frank, Ginger Haynes, Thomas P. Laughren, James McNulty, Shelby D. Reed, Juan Sanchez, and Andrew C. Leon. “Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials.” Innov Clin Neurosci 10, no. 5-6 Suppl A (May 2013): 4S-19S.
       Link to Item
    • Vita, Antonio, Giacomo Deste, Stefano Barlati, Luca De Peri, Agnese Giambra, Roberto Poli, Richard S. E. Keefe, and Emilio Sacchetti. “Interview-based assessment of cognition in schizophrenia: applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care.” Schizophr Res 146, no. 1–3 (May 2013): 217–23. https://doi.org/10.1016/j.schres.2013.02.035.
       Full Text  Link to Item
    • Sakurai, Hitoshi, Robert R. Bies, Scott T. Stroup, Richard S. E. Keefe, Tarek K. Rajji, Takefumi Suzuki, David C. Mamo, et al. “Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.” Schizophr Bull 39, no. 3 (May 2013): 564–74. https://doi.org/10.1093/schbul/sbr189.
       Full Text  Link to Item
    • Ventura, Joseph, Steven P. Reise, Richard S. E. Keefe, Irene M. Hurford, Rachel C. Wood, and Robert M. Bilder. “The Cognitive Assessment Interview (CAI): reliability and validity of a brief interview-based measure of cognition.” Schizophr Bull 39, no. 3 (May 2013): 583–91. https://doi.org/10.1093/schbul/sbs001.
       Full Text  Link to Item
    • Barbato, Mariapaola, Mark A. Colijn, Richard S. E. Keefe, Diana O. Perkins, Scott W. Woods, Keith A. Hawkins, Bruce K. Christensen, and Jean Addington. “The course of cognitive functioning over six months in individuals at clinical high risk for psychosis.” Psychiatry Res 206, no. 2–3 (April 30, 2013): 195–99. https://doi.org/10.1016/j.psychres.2012.10.013.
       Full Text  Link to Item
    • Lam, Max, Goi Khia Eng, Attilio Rapisarda, Mythily Subramaniam, Michael Kraus, Richard S. E. Keefe, and Simon Lowes Collinson. “Formulation of the age-education index: measuring age and education effects in neuropsychological performance.” Psychol Assess 25, no. 1 (March 2013): 61–70. https://doi.org/10.1037/a0030548.
       Full Text  Link to Item
    • Keefe, Richard S. E., Robert W. Buchanan, Stephen R. Marder, Nina R. Schooler, Ashish Dugar, Milana Zivkov, and Michelle Stewart. “Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?” Schizophr Bull 39, no. 2 (March 2013): 417–35. https://doi.org/10.1093/schbul/sbr153.
       Full Text  Link to Item
    • Kim, Jeong Lan, Shilpa Rele, David M. Marks, Prakash S. Masand, Pallavi Yerramsetty, Robert A. Millet, Richard S. Keefe, and Ashwin A. Patkar. “Effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial.” Prim Care Companion Cns Disord 15, no. 6 (2013). https://doi.org/10.4088/PCC.13m01555.
       Full Text  Link to Item
    • Lee, Tih-Shih, Siau Juinn Alexa Goh, Shin Yi Quek, Rachel Phillips, Cuntai Guan, Yin Bun Cheung, Lei Feng, et al. “A brain-computer interface based cognitive training system for healthy elderly: a randomized control pilot study for usability and preliminary efficacy.” Plos One 8, no. 11 (2013): e79419. https://doi.org/10.1371/journal.pone.0079419.
       Full Text  Link to Item
    • Rapisarda, Attilio, Thomas F. Lim, Matthew Lim, Simon L. Collinson, Michael S. Kraus, and Richard S. E. Keefe. “Applicability of the MATRICS Consensus Cognitive Battery in Singapore.” Clin Neuropsychol 27, no. 3 (2013): 455–69. https://doi.org/10.1080/13854046.2012.762120.
       Full Text  Link to Item
    • Matza, Louis S., Glenn A. Phillips, Dennis A. Revicki, Haya Ascher-Svanum, Karen G. Malley, Andrew C. Palsgrove, Douglas E. Faries, et al. “Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia.” Psychiatry Res 200, no. 2–3 (December 30, 2012): 835–42. https://doi.org/10.1016/j.psychres.2012.05.005.
       Full Text  Link to Item
    • Harvey, P. D., and R. S. Keefe. “Technology, society, and mental illness: Challenges and opportunities for assessment and treatment.” Innovations in Clinical Neuroscience 9, no. 11–12 (December 1, 2012): 47–50.
    • Kahn, Phoebe V., Trina M. Walker, Teresa S. Williams, Barbara A. Cornblatt, Richard C. Mohs, and Richard S. E. Keefe. “Standardizing the use of the Continuous Performance Test in schizophrenia research: a validation study.” Schizophr Res 142, no. 1–3 (December 2012): 153–58. https://doi.org/10.1016/j.schres.2012.09.009.
       Full Text  Link to Item
    • Meier, Madeline H., Avshalom Caspi, Antony Ambler, HonaLee Harrington, Renate Houts, Richard S. E. Keefe, Kay McDonald, Aimee Ward, Richie Poulton, and Terrie E. Moffitt. “Persistent cannabis users show neuropsychological decline from childhood to midlife.” Proc Natl Acad Sci U S A 109, no. 40 (October 2, 2012): E2657–64. https://doi.org/10.1073/pnas.1206820109.
       Full Text  Link to Item
    • Geffen, Yona, Richard Keefe, Jonathan Rabinowitz, Ravi Anand, and Michael Davidson. “Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.” J Clin Psychiatry 73, no. 9 (September 2012): e1168–74. https://doi.org/10.4088/JCP.12m07642.
       Full Text  Link to Item
    • Keefe, Richard S. E., Sophia Vinogradov, Alice Medalia, Peter F. Buckley, Stanley N. Caroff, Deepak C. D’Souza, Phillip D. Harvey, et al. “Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial.” J Clin Psychiatry 73, no. 7 (July 2012): 1016–22. https://doi.org/10.4088/JCP.11m07100.
       Full Text  Link to Item
    • Weiser, Mark, Ari A. Gershon, Katya Rubinstein, Camelia Petcu, Maria Ladea, Dorina Sima, Delia Podea, Richard S. E. Keefe, and John M. Davis. “A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder.” Schizophr Res 138, no. 1 (June 2012): 35–38. https://doi.org/10.1016/j.schres.2012.02.014.
       Full Text  Link to Item
    • Keefe, Richard S. E., and Michael S. Kraus. “Clues to the cognitive and perceptual origins of social isolation and psychosis in schizophrenia.” Am J Psychiatry 169, no. 4 (April 2012): 354–57. https://doi.org/10.1176/appi.ajp.2012.12010042.
       Full Text  Link to Item
    • Javitt, Daniel C., Robert W. Buchanan, Richard S. E. Keefe, Robert Kern, Robert P. McMahon, Michael F. Green, Jeffrey Lieberman, et al. “Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.” Schizophr Res 136, no. 1–3 (April 2012): 25–31. https://doi.org/10.1016/j.schres.2011.11.001.
       Full Text  Link to Item
    • Keefe, Richard S. E., and Philip D. Harvey. “Cognitive impairment in schizophrenia.” Handb Exp Pharmacol, no. 213 (2012): 11–37. https://doi.org/10.1007/978-3-642-25758-2_2.
       Full Text  Link to Item
    • Krishnan, R. R., M. Fivaz, M. S. Kraus, and R. S. E. Keefe. “Erratum: Hierarchical temporal processing deficit model of reality distortion and psychoses (Molecular Psychiatry (2011) 16, (129-144) DOI: 10.1038/mp.2010.63).” Molecular Psychiatry 17, no. 4 (January 1, 2012): 470. https://doi.org/10.1038/mp.2011.54.
       Full Text
    • Matza, Louis S., Glenn A. Phillips, Dennis A. Revicki, Haya Ascher-Svanum, Karen G. Malley, Andrew C. Palsgrove, Douglas E. Faries, et al. “Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation.” Patient Prefer Adherence 6 (2012): 521–32. https://doi.org/10.2147/PPA.S25635.
       Full Text  Link to Item
    • Greenberg, Greg, Robert A. Rosenheck, Steven K. Erickson, Rani A. Desai, Elina A. Stefanovics, Marvin Swartz, Richard S. E. Keefe, Joe McEvoy, T Scott Stroup, and T Scott CATIE Investigators. “Criminal justice system involvement among people with schizophrenia.” Community Ment Health J 47, no. 6 (December 2011): 727–36. https://doi.org/10.1007/s10597-010-9362-9.
       Full Text  Link to Item
    • Buchanan, Robert W., Richard S. E. Keefe, Daniel Umbricht, Michael F. Green, Thomas Laughren, and Stephen R. Marder. “The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?” Schizophr Bull 37, no. 6 (November 2011): 1209–17. https://doi.org/10.1093/schbul/sbq038.
       Full Text  Link to Item
    • Kerfoot, Karin E., Robert A. Rosenheck, Ismene L. Petrakis, Marvin S. Swartz, Richard S. E. Keefe, Joseph P. McEvoy, T Scott Stroup, and T Scott CATIE Investigators. “Substance use and schizophrenia: adverse correlates in the CATIE study sample.” Schizophr Res 132, no. 2–3 (November 2011): 177–82. https://doi.org/10.1016/j.schres.2011.07.032.
       Full Text  Link to Item
    • Chong, Siow-Ann, Alastair Campbell, Michael Chee, Jianjun Liu, Christine Marx, Patrick McGorry, Mythily Subramaniam, Alison Yung, and Richard S. E. Keefe. “The Singapore flagship programme in translational and clinical research in psychosis.” Early Interv Psychiatry 5, no. 4 (November 2011): 290–300. https://doi.org/10.1111/j.1751-7893.2011.00304.x.
       Full Text  Link to Item
    • Keefe, Richard S. E., Sophia Vinogradov, Alice Medalia, Steven M. Silverstein, Morris D. Bell, Dwight Dickinson, Joseph Ventura, Stephen R. Marder, and T Scott Stroup. “Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia.” Schizophr Bull 37, no. 5 (September 2011): 1057–65. https://doi.org/10.1093/schbul/sbq010.
       Full Text  Link to Item
    • Stroup, T Scott, Paul S. Appelbaum, Hongbin Gu, Spencer Hays, Marvin S. Swartz, Richard S. E. Keefe, Scott Y. Kim, et al. “Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study.” Schizophr Res 130, no. 1–3 (August 2011): 47–52. https://doi.org/10.1016/j.schres.2011.04.012.
       Full Text  Link to Item
    • Vigen, Cheryl L. P., Wendy J. Mack, Richard S. E. Keefe, Mary Sano, David L. Sultzer, T Scott Stroup, Karen S. Dagerman, et al. “Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.” Am J Psychiatry 168, no. 8 (August 2011): 831–39. https://doi.org/10.1176/appi.ajp.2011.08121844.
       Full Text  Link to Item
    • Burdick, Katherine E., Terry E. Goldberg, Barbara A. Cornblatt, Richard S. Keefe, Chaya B. Gopin, Pamela Derosse, Raphael J. Braga, and Anil K. Malhotra. “The MATRICS consensus cognitive battery in patients with bipolar I disorder.” Neuropsychopharmacology 36, no. 8 (July 2011): 1587–92. https://doi.org/10.1038/npp.2011.36.
       Full Text  Link to Item
    • Krishnan, Ranga R., Michael S. Kraus, and Richard S. E. Keefe. “Comprehensive model of how reality distortion and symptoms occur in schizophrenia: could impairment in learning-dependent predictive perception account for the manifestations of schizophrenia?” Psychiatry Clin Neurosci 65, no. 4 (June 2011): 305–17. https://doi.org/10.1111/j.1440-1819.2011.02203.x.
       Full Text  Link to Item
    • Hurford, Irene M., Stephen R. Marder, Richard S. E. Keefe, Steven P. Reise, and Robert M. Bilder. “A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians.” Schizophr Bull 37, no. 3 (May 2011): 538–45. https://doi.org/10.1093/schbul/sbp095.
       Full Text  Link to Item
    • Sim, Kang, Jimmy Lee, Mythily Subramaniam, Jian Jun Liu, Richard Keefe, Xiao Dong Zhang, Tih Shih Lee, and Siow Ann Chong. “Integrated genetic and genomic approach in the SingaporeTranslational and Clinical Research in Psychosis Study: an overview.” Early Interv Psychiatry 5, no. 2 (May 2011): 91–99. https://doi.org/10.1111/j.1751-7893.2011.00272.x.
       Full Text  Link to Item
    • Harvey, Philip D., Masaaki Ogasa, Josephine Cucchiaro, Antony Loebel, and Richard S. E. Keefe. “Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.” Schizophr Res 127, no. 1–3 (April 2011): 188–94. https://doi.org/10.1016/j.schres.2011.01.004.
       Full Text  Link to Item
    • Buchanan, Robert W., Richard S. E. Keefe, Jeffrey A. Lieberman, Deanna M. Barch, John G. Csernansky, Donald C. Goff, James M. Gold, et al. “A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.” Biol Psychiatry 69, no. 5 (March 1, 2011): 442–49. https://doi.org/10.1016/j.biopsych.2010.09.052.
       Full Text  Link to Item
    • Caroff, Stanley N., Vicki G. Davis, Del D. Miller, Sonia M. Davis, Robert A. Rosenheck, Joseph P. McEvoy, E Cabrina Campbell, et al. “Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.” J Clin Psychiatry 72, no. 3 (March 2011): 295–303. https://doi.org/10.4088/JCP.09m05793yel.
       Full Text  Link to Item
    • Kern, Robert S., James M. Gold, Dwight Dickinson, Michael F. Green, Keith H. Nuechterlein, Lyle E. Baade, Richard S. E. Keefe, et al. “The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study.” Schizophr Res 126, no. 1–3 (March 2011): 124–31. https://doi.org/10.1016/j.schres.2010.11.008.
       Full Text  Link to Item
    • Marder, Stephen R., David G. Daniel, Larry Alphs, A George Awad, and Richard S. E. Keefe. “Methodological issues in negative symptom trials.” Schizophr Bull 37, no. 2 (March 2011): 250–54. https://doi.org/10.1093/schbul/sbq161.
       Full Text  Link to Item
    • Reise, Steven P., Joseph Ventura, Richard S. E. Keefe, Lyle E. Baade, James M. Gold, Michael F. Green, Robert S. Kern, et al. “Bifactor and item response theory analyses of interviewer report scales of cognitive impairment in schizophrenia.” Psychol Assess 23, no. 1 (March 2011): 245–61. https://doi.org/10.1037/a0021501.
       Full Text  Link to Item
    • Sachs, G., B. Winklbaur, R. Jagsch, and R. S. E. Keefe. “Validation of the German version of the brief assessment of cognition in Schizophrenia (BACS) - preliminary results.” Eur Psychiatry 26, no. 2 (March 2011): 74–77. https://doi.org/10.1016/j.eurpsy.2009.10.006.
       Full Text  Link to Item
    • Segarra, N., M. Bernardo, F. Gutierrez, A. Justicia, E. Fernadez-Egea, M. Allas, G. Safont, et al. “Spanish validation of the Brief Assessment in Cognition in Schizophrenia (BACS) in patients with schizophrenia and healthy controls.” Eur Psychiatry 26, no. 2 (March 2011): 69–73. https://doi.org/10.1016/j.eurpsy.2009.11.001.
       Full Text  Link to Item
    • Keefe, Richard S. E., Kolleen Hurley Fox, Philip D. Harvey, Josephine Cucchiaro, Cynthia Siu, and Antony Loebel. “Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.” Schizophr Res 125, no. 2–3 (February 2011): 161–68. https://doi.org/10.1016/j.schres.2010.09.015.
       Full Text  Link to Item
    • Krishnan, R. R., M. Fivaz, M. S. Kraus, and R. S. E. Keefe. “Hierarchical temporal processing deficit model of reality distortion and psychoses.” Mol Psychiatry 16, no. 2 (February 2011): 129–44. https://doi.org/10.1038/mp.2010.63.
       Full Text  Link to Item
    • McClay, Joseph L., Daniel E. Adkins, Karolina Aberg, Jozsef Bukszár, Amit N. Khachane, Richard S. E. Keefe, Diana O. Perkins, et al. “Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.” Neuropsychopharmacology 36, no. 3 (February 2011): 616–26. https://doi.org/10.1038/npp.2010.193.
       Full Text  Link to Item
    • Keefe, Richard S. E., Michael S. Kraus, and Ranga R. Krishnan. “Failures in learning-dependent predictive perception as the key cognitive vulnerability to psychosis in schizophrenia.” Neuropsychopharmacology 36, no. 1 (January 2011): 367–68. https://doi.org/10.1038/npp.2010.153.
       Full Text  Link to Item
    • Kane, John M., Deepak C. D’Souza, Ashwin A. Patkar, James M. Youakim, Jane M. Tiller, Ronghua Yang, and Richard S. E. Keefe. “Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.” J Clin Psychiatry 71, no. 11 (November 2010): 1475–81. https://doi.org/10.4088/JCP.09m05950gry.
       Full Text  Link to Item
    • Ascher-Svanum, Haya, Allen W. Nyhuis, Virginia Stauffer, Bruce J. Kinon, Douglas E. Faries, Glenn A. Phillips, Kory Schuh, A George Awad, Richard Keefe, and Dieter Naber. “Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives.” Curr Med Res Opin 26, no. 10 (October 2010): 2403–10. https://doi.org/10.1185/03007995.2010.515900.
       Full Text  Link to Item
    • Ventura, Joseph, Steven P. Reise, Richard S. E. Keefe, Lyle E. Baade, James M. Gold, Michael F. Green, Robert S. Kern, et al. “The Cognitive Assessment Interview (CAI): development and validation of an empirically derived, brief interview-based measure of cognition.” Schizophr Res 121, no. 1–3 (August 2010): 24–31. https://doi.org/10.1016/j.schres.2010.04.016.
       Full Text  Link to Item
    • Konneker, Thomas I., James J. Crowley, Corey R. Quackenbush, Richard S. E. Keefe, Diana O. Perkins, T Scott Stroup, Jeffrey A. Lieberman, Edwin van den Oord, and Patrick F. Sullivan. “No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition.” Am J Med Genet B Neuropsychiatr Genet 153B, no. 5 (July 2010): 1115–17. https://doi.org/10.1002/ajmg.b.31077.
       Full Text  Link to Item
    • Chia, Ming Ying, Wai Yen Chan, Kok Yeow Chua, Helen Lee, Jimmy Lee, Rebecca Lee, Caroline Lim, et al. “The Schizophrenia Cognition Rating Scale: validation of an interview-based assessment of cognitive functioning in Asian patients with schizophrenia.” Psychiatry Res 178, no. 1 (June 30, 2010): 33–38. https://doi.org/10.1016/j.psychres.2010.03.020.
       Full Text  Link to Item
    • Chan, Wai-Yen, Guo-Liang Yang, Ming-Ying Chia, Puay-San Woon, Jimmy Lee, Richard Keefe, Yih-Yian Sitoh, Wieslaw Lucjan Nowinski, and Kang Sim. “Cortical and subcortical white matter abnormalities in adults with remitted first-episode mania revealed by Tract-Based Spatial Statistics.” Bipolar Disord 12, no. 4 (June 2010): 383–89. https://doi.org/10.1111/j.1399-5618.2010.00829.x.
       Full Text  Link to Item
    • Seidman, Larry J., Anthony J. Giuliano, Eric C. Meyer, Jean Addington, Kristin S. Cadenhead, Tyrone D. Cannon, Thomas H. McGlashan, et al. “Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis.” Arch Gen Psychiatry 67, no. 6 (June 2010): 578–88. https://doi.org/10.1001/archgenpsychiatry.2010.66.
       Full Text  Link to Item
    • Goldberg, Terry E., Richard S. E. Keefe, Robert S. Goldman, Delbert G. Robinson, and Philip D. Harvey. “Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies.” Neuropsychopharmacology 35, no. 5 (April 2010): 1053–62. https://doi.org/10.1038/npp.2009.211.
       Full Text  Link to Item
    • Polanczyk, Guilherme, Terrie E. Moffitt, Louise Arseneault, Mary Cannon, Antony Ambler, Richard S. E. Keefe, Renate Houts, Candice L. Odgers, and Avshalom Caspi. “Etiological and clinical features of childhood psychotic symptoms: results from a birth cohort.” Arch Gen Psychiatry 67, no. 4 (April 2010): 328–38. https://doi.org/10.1001/archgenpsychiatry.2010.14.
       Full Text  Link to Item
    • Reichenberg, Abraham, Avshalom Caspi, Honalee Harrington, Renate Houts, Richard S. E. Keefe, Robin M. Murray, Richie Poulton, and Terrie E. Moffitt. “Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study.” Am J Psychiatry 167, no. 2 (February 2010): 160–69. https://doi.org/10.1176/appi.ajp.2009.09040574.
       Full Text  Link to Item
    • Barch, Deanna M., and Richard S. E. Keefe. “Anticipating DSM-V: opportunities and challenges for cognition and psychosis.” Schizophr Bull 36, no. 1 (January 2010): 43–47. https://doi.org/10.1093/schbul/sbp139.
       Full Text  Link to Item
    • Keefe, R. S. E. “Neurocognition,” January 1, 2010, 97–119. https://doi.org/10.1017/CBO9780511712265.007.
       Full Text
    • Lamonica, Haley M., Richard S. E. Keefe, Philip D. Harvey, James M. Gold, and Terry E. Goldberg. “Differential effects of emotional information on interference task performance across the life span.” Front Aging Neurosci 2 (2010). https://doi.org/10.3389/fnagi.2010.00141.
       Full Text  Link to Item
    • Pinheiro, A. P., R. S. E. Keefe, T. Skelly, M. Olarte, K. Leviel, L. A. Lange, E. M. Lange, T. S. Stroup, J. Lieberman, and P. F. Sullivan. “Erratum: AKT1 and neurocognition in schizophrenia (Australian and New Zealand Journal of Psychiatry (2007) 41 (169-177)).” Australian and New Zealand Journal of Psychiatry 43, no. 10 (December 8, 2009): 983. https://doi.org/10.1080/00048670903228991.
       Full Text
    • Fox, K. H., K. E. Burdick, I. Lombardo, and R. S. E. Keefe. “Cognitive impairment in patients with bipolar disorder.” Psychiatric Times 26, no. 12 (December 1, 2009): 66–68.
    • Penn, David L., Richard S. E. Keefe, Sonia M. Davis, Piper S. Meyer, Diana O. Perkins, Diane Losardo, and Jeffrey A. Lieberman. “The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial.” Schizophr Res 115, no. 1 (November 2009): 17–23. https://doi.org/10.1016/j.schres.2009.08.016.
       Full Text  Link to Item
    • Pinheiro, A. P., R. S. E. Keefe, T. Skelly, M. Olarte, K. Leviel, L. A. Lange, E. M. Lange, T. S. Stroup, J. Lieberman, and P. F. Sullivan. “Erratum: Rates of depressive and anxiety disorders in a residential mother-infant unit for unsettled infants (Australian and New Zealand Journal of Psychiatry (2007) 41 (836-842)).” Australian and New Zealand Journal of Psychiatry 43, no. 11 (November 1, 2009): 1087. https://doi.org/10.1080/00048670903270266.
       Full Text
    • Keefe, R. S. E., L. J. Seidman, B. K. Christensen, R. M. Hamer, T. Sharma, M. M. Sitskoorn, R. R. J. Lewine, et al. “Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: A randomized, double-blind trial of olanzapine versus low doses of haloperidol (American Journal of Psychiatry (2004) 161, (985-995)).” American Journal of Psychiatry 166, no. 8 (September 21, 2009): 942.
    • Kraus, Michael S., Richard S. E. Keefe, and Ranga K. R. Krishnan. “Memory-prediction errors and their consequences in schizophrenia.” Neuropsychol Rev 19, no. 3 (September 2009): 336–52. https://doi.org/10.1007/s11065-009-9106-1.
       Full Text  Link to Item
    • Lipkovich, Ilya A., Walter Deberdt, John G. Csernansky, Bernard Sabbe, Richard Se Keefe, and Sara Kollack-Walker. “Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy.” Bmc Psychiatry 9 (July 14, 2009): 44. https://doi.org/10.1186/1471-244X-9-44.
       Full Text  Link to Item
    • Marx, Christine E., Richard S. E. Keefe, Robert W. Buchanan, Robert M. Hamer, Jason D. Kilts, Daniel W. Bradford, Jennifer L. Strauss, et al. “Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia.” Neuropsychopharmacology 34, no. 8 (July 2009): 1885–1903. https://doi.org/10.1038/npp.2009.26.
       Full Text  Link to Item
    • Need, Anna C., Richard S. E. Keefe, Dongliang Ge, Iris Grossman, Sam Dickson, Joseph P. McEvoy, and David B. Goldstein. “Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis.” Eur J Hum Genet 17, no. 7 (July 2009): 946–57. https://doi.org/10.1038/ejhg.2008.264.
       Full Text  Link to Item
    • Krishnan, Ranga R., Richard Keefe, and Michael Kraus. “Schizophrenia is a disorder of higher order hierarchical processing.” Med Hypotheses 72, no. 6 (June 2009): 740–44. https://doi.org/10.1016/j.mehy.2008.12.039.
       Full Text  Link to Item
    • Davidson, Michael, Silvana Galderisi, Mark Weiser, Nomi Werbeloff, Wolfgang W. Fleischhacker, Richard S. Keefe, Han Boter, et al. “Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).” Am J Psychiatry 166, no. 6 (June 2009): 675–82. https://doi.org/10.1176/appi.ajp.2008.08060806.
       Full Text  Link to Item
    • Sim, Kang, Guo Liang Yang, Donus Loh, Lye Yin Poon, Yih Yian Sitoh, Swapna Verma, Richard Keefe, et al. “White matter abnormalities and neurocognitive deficits associated with the passivity phenomenon in schizophrenia: a diffusion tensor imaging study.” Psychiatry Res 172, no. 2 (May 15, 2009): 121–27. https://doi.org/10.1016/j.pscychresns.2009.02.003.
       Full Text  Link to Item
    • Harvey, Philip D., Richard S. E. Keefe, Thomas L. Patterson, Robert K. Heaton, and Christopher R. Bowie. “Abbreviated neuropsychological assessment in schizophrenia: prediction of different aspects of outcome.” J Clin Exp Neuropsychol 31, no. 4 (May 2009): 462–71. https://doi.org/10.1080/13803390802251386.
       Full Text  Link to Item
    • Keefe, Richard S. E., and Michael S. Kraus. “Measuring memory-prediction errors and their consequences in youth at risk for schizophrenia.” Ann Acad Med Singap 38, no. 5 (May 2009): 414–16.
       Link to Item
    • Lim, Caroline, Siow Ann Chong, and Richard S. E. Keefe. “Psychosocial factors in the neurobiology of schizophrenia: a selective review.” Ann Acad Med Singap 38, no. 5 (May 2009): 402–6.
       Link to Item
    • Tiller, Jane, Deepak C. D’Souza, Richard S. E. Keefe, John M. Kane, Ashwin A. Patkar, and James M. Youakim. “Effects of Adjunctive Armodafinil on Patients with Schizophrenia.” Neurology 72, no. 11 (March 17, 2009): A336–A336.
       Link to Item
    • Kane, John M., D. C. D’Souza, A. A. Patkar, J. M. Youakim, J. Tiller, R. Yang, and R. S. Keefe. “EFFICACY AND TOLERABILITY OF ADJUNCTIVE ARMODAFINIL IN PATIENTS WITH SCHIZOPHRENIA.” Schizophrenia Bulletin 35 (March 1, 2009): 356–57.
       Link to Item
    • Marx, Christine E., R. S. Keefe, V. M. Payne, J. D. Kilts, J. L. Strauss, J. C. Naylor, R. M. Hamer, et al. “NEUROSTEROIDS AS NOVEL THERAPEUTIC AGENTS IN SCHIZOPHRENIA AND PTSD.” Schizophrenia Bulletin 35 (March 1, 2009): 368–368.
       Link to Item
    • Kern, Robert S., Michael F. Green, Keith H. Nuechterlein, and Richard S. E. Keefe. “CMINDS does not have identical tests to the CATIE and MATRICS batteries. Commentary on O'Halloran et al.” Schizophr Res 107, no. 2–3 (February 2009): 327–29. https://doi.org/10.1016/j.schres.2008.10.015.
       Full Text  Link to Item
    • Kleinman, Leah, Jeffrey Lieberman, Sanjay Dube, Richard Mohs, Yang Zhao, Bruce Kinon, William Carpenter, et al. “Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function.” Schizophr Res 107, no. 2–3 (February 2009): 275–85. https://doi.org/10.1016/j.schres.2008.10.002.
       Full Text  Link to Item
    • Need, Anna C., Dongliang Ge, Michael E. Weale, Jessica Maia, Sheng Feng, Erin L. Heinzen, Kevin V. Shianna, et al. “A genome-wide investigation of SNPs and CNVs in schizophrenia.” Plos Genet 5, no. 2 (February 2009): e1000373. https://doi.org/10.1371/journal.pgen.1000373.
       Full Text  Link to Item
    • Pinheiro, A. P., R. S. E. Keefe, T. Skelly, M. Olarte, K. Leviel, L. A. Lange, E. M. Lange, T. S. Stroup, J. Lieberman, and P. F. Sullivan. “AKT1 and neurocognition in schizophrenia (vol 41, pg 169, 2007).” Australian and New Zealand Journal of Psychiatry 43, no. 10 (January 1, 2009): 983–983.
       Link to Item
    • Stroup, T Scott, Jeffrey A. Lieberman, Joseph P. McEvoy, Sonia M. Davis, Marvin S. Swartz, Richard S. E. Keefe, Alexander L. Miller, Robert A. Rosenheck, John K. Hsiao, and John K. CATIE Investigators. “Results of phase 3 of the CATIE schizophrenia trial.” Schizophr Res 107, no. 1 (January 2009): 1–12. https://doi.org/10.1016/j.schres.2008.10.011.
       Full Text  Link to Item
    • Targum, Steven D., and Richard S. E. Keefe. “Cognition and schizophrenia: is there a role for cognitive assessments in diagnosis and treatment?” Psychiatry (Edgmont) 5, no. 12 (December 2008): 55–59.
       Link to Item
    • Crowley, James J., Richard S. E. Keefe, Diana O. Perkins, T Scott Stroup, Jeffrey A. Lieberman, and Patrick F. Sullivan. “The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition.” Am J Med Genet B Neuropsychiatr Genet 147B, no. 7 (October 5, 2008): 1298–1300. https://doi.org/10.1002/ajmg.b.30727.
       Full Text  Link to Item
    • Hawkins, Keith A., Richard S. E. Keefe, Bruce K. Christensen, Jean Addington, Scott W. Woods, Jennifer Callahan, Robert B. Zipursky, et al. “Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study.” Schizophr Res 105, no. 1–3 (October 2008): 1–9. https://doi.org/10.1016/j.schres.2008.07.008.
       Full Text  Link to Item
    • Miller, Del D., Stanley N. Caroff, Sonia M. Davis, Robert A. Rosenheck, Joseph P. McEvoy, Bruce L. Saltz, Silvana Riggio, et al. “Extrapyramidal side-effects of antipsychotics in a randomised trial.” Br J Psychiatry 193, no. 4 (October 2008): 279–88. https://doi.org/10.1192/bjp.bp.108.050088.
       Full Text  Link to Item
    • Mohamed, Somaia, Robert Rosenheck, Marvin Swartz, Scott Stroup, Jeffrey A. Lieberman, and Richard S. E. Keefe. “Relationship of cognition and psychopathology to functional impairment in schizophrenia.” Am J Psychiatry 165, no. 8 (August 2008): 978–87. https://doi.org/10.1176/appi.ajp.2008.07111713.
       Full Text  Link to Item
    • Keefe, Richard S. E., Philip D. Harvey, Terry E. Goldberg, James M. Gold, Trina M. Walker, Courtney Kennel, and Kirsten Hawkins. “Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS).” Schizophr Res 102, no. 1–3 (July 2008): 108–15. https://doi.org/10.1016/j.schres.2008.03.024.
       Full Text  Link to Item
    • Keefe, Richard S. E., and Philip D. Harvey. “Implementation considerations for multisite clinical trials with cognitive neuroscience tasks.” Schizophr Bull 34, no. 4 (July 2008): 656–63. https://doi.org/10.1093/schbul/sbn042.
       Full Text  Link to Item
    • Keefe, Richard S. E., Anil K. Malhotra, Herbert Y. Meltzer, John M. Kane, Robert W. Buchanan, Anita Murthy, Mindy Sovel, Chunming Li, and Robert Goldman. “Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.” Neuropsychopharmacology 33, no. 6 (May 2008): 1217–28. https://doi.org/10.1038/sj.npp.1301499.
       Full Text  Link to Item
    • Swartz, Marvin S., T Scott Stroup, Joseph P. McEvoy, Sonia M. Davis, Robert A. Rosenheck, Richard S. E. Keefe, John K. Hsiao, and Jeffrey A. Lieberman. “What CATIE found: results from the schizophrenia trial.” Psychiatr Serv 59, no. 5 (May 2008): 500–506. https://doi.org/10.1176/ps.2008.59.5.500.
       Full Text  Link to Item
    • Lieberman, Jeffrey A., Robert E. Drake, Lloyd I. Sederer, Aysenil Belger, Richard Keefe, Diana Perkins, and Scott Stroup. “Science and recovery in schizophrenia.” Psychiatr Serv 59, no. 5 (May 2008): 487–96. https://doi.org/10.1176/ps.2008.59.5.487.
       Full Text  Link to Item
    • Resnick, Sandra G., Robert A. Rosenheck, Jose M. Canive, Cyril De Souza, T Scott Stroup, Joseph McEvoy, Sonia Davis, Richard S. E. Keefe, Marvin Swartz, and Jeffrey Lieberman. “Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia.” J Behav Health Serv Res 35, no. 2 (April 2008): 215–25. https://doi.org/10.1007/s11414-007-9101-3.
       Full Text  Link to Item
    • Hill, S Kristian, John A. Sweeney, Robert M. Hamer, Richard S. E. Keefe, Diana O. Perkins, Hongbin Gu, Joseph P. McEvoy, and Jeffrey A. Lieberman. “Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia.” J Int Neuropsychol Soc 14, no. 2 (March 2008): 209–21. https://doi.org/10.1017/S1355617708080570.
       Full Text  Link to Item
    • Green, Michael F., Keith H. Nuechterlein, Robert S. Kern, Lyle E. Baade, Wayne S. Fenton, James M. Gold, Richard S. E. Keefe, et al. “Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.” Am J Psychiatry 165, no. 2 (February 2008): 221–28. https://doi.org/10.1176/appi.ajp.2007.07010089.
       Full Text  Link to Item
    • Keefe, Richard S. E. “Should cognitive impairment be included in the diagnostic criteria for schizophrenia?” World Psychiatry 7, no. 1 (February 2008): 22–28. https://doi.org/10.1002/j.2051-5545.2008.tb00142.x.
       Full Text  Link to Item
    • Kern, Robert S., Keith H. Nuechterlein, Michael F. Green, Lyle E. Baade, Wayne S. Fenton, James M. Gold, Richard S. E. Keefe, et al. “The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.” Am J Psychiatry 165, no. 2 (February 2008): 214–20. https://doi.org/10.1176/appi.ajp.2007.07010043.
       Full Text  Link to Item
    • Nuechterlein, Keith H., Michael F. Green, Robert S. Kern, Lyle E. Baade, Deanna M. Barch, Jonathan D. Cohen, Susan Essock, et al. “The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.” Am J Psychiatry 165, no. 2 (February 2008): 203–13. https://doi.org/10.1176/appi.ajp.2007.07010042.
       Full Text  Link to Item
    • Goff, Donald C., Richard Keefe, Leslie Citrome, Katherine Davy, John H. Krystal, Charles Large, Thomas R. Thompson, Jan Volavka, and Elizabeth L. Webster. “Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials.” J Clin Psychopharmacol 27, no. 6 (December 2007): 582–89. https://doi.org/10.1097/jcp.0b013e31815abf34.
       Full Text  Link to Item
    • Kaneda, Yasuhiro, Tomiki Sumiyoshi, Richard Keefe, Yasuhito Ishimoto, Shusuke Numata, and Tetsuro Ohmori. “Brief assessment of cognition in schizophrenia: validation of the Japanese version.” Psychiatry Clin Neurosci 61, no. 6 (December 2007): 602–9. https://doi.org/10.1111/j.1440-1819.2007.01725.x.
       Full Text  Link to Item
    • Keefe, R. S. E., J. A. Sweeney, H. Gu, R. M. Hamer, D. O. Perkins, J. P. McEvoy, and J. A. Lieberman. “Dr. Keefe and colleagues reply.” American Journal of Psychiatry 164, no. 12 (December 1, 2007): 1911–12. https://doi.org/10.1176/appi.ajp.2007.07071086r.
       Full Text
    • Bralet, Marie-Cécile, Bruno Falissard, Xavier Neveu, Margaret Lucas-Ross, Anne-Marie Eskenazi, and Richard S. E. Keefe. “Validation of the French version of the BACS (the brief assessment of cognition in schizophrenia) among 50 French schizophrenic patients.” Eur Psychiatry 22, no. 6 (September 2007): 365–70. https://doi.org/10.1016/j.eurpsy.2007.02.001.
       Full Text  Link to Item
    • Kraus, Michael S., and Richard S. E. Keefe. “Cognition as an outcome measure in schizophrenia.” Br J Psychiatry Suppl 50 (August 2007): s46–51. https://doi.org/10.1192/bjp.191.50.s46.
       Full Text  Link to Item
    • Pandina, Gahan J., Robert Bilder, Philip D. Harvey, Richard S. E. Keefe, Michael G. Aman, and Georges Gharabawi. “Risperidone and cognitive function in children with disruptive behavior disorders.” Biol Psychiatry 62, no. 3 (August 1, 2007): 226–34. https://doi.org/10.1016/j.biopsych.2006.09.036.
       Full Text  Link to Item
    • Keefe, Richard S. E., John A. Sweeney, Hongbin Gu, Robert M. Hamer, Diana O. Perkins, Joseph P. McEvoy, and Jeffrey A. Lieberman. “Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.” Am J Psychiatry 164, no. 7 (July 2007): 1061–71. https://doi.org/10.1176/ajp.2007.164.7.1061.
       Full Text  Link to Item
    • Keefe, Richard S. E., and Wayne S. Fenton. “How should DSM-V criteria for schizophrenia include cognitive impairment?” Schizophr Bull 33, no. 4 (July 2007): 912–20. https://doi.org/10.1093/schbul/sbm046.
       Full Text  Link to Item
    • Salgado, João Vinícius, Carolina F Richards Carvalhaes, Annelise de Matos Pires, Maila de Castro L das Neves, Breno Fiúza Cruz, Clareci Silva Cardoso, Helio Lauar, Antonio Lúcio Teixeira, and Richard S. E. Keefe. “Sensitivity and applicability of the Brazilian version of the Brief Assessment of Cognition in Schizophrenia (BACS).” Dement Neuropsychol 1, no. 3 (July 2007): 260–65. https://doi.org/10.1590/S1980-57642008DN10300007.
       Full Text  Link to Item
    • Keefe, Richard S. E., Robert M. Bilder, Sonia M. Davis, Philip D. Harvey, Barton W. Palmer, James M. Gold, Herbert Y. Meltzer, et al. “Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.” Arch Gen Psychiatry 64, no. 6 (June 2007): 633–47. https://doi.org/10.1001/archpsyc.64.6.633.
       Full Text  Link to Item
    • ROSENHECK, R., T. S. STROUP, M. SWARTZ, J. McEVOY, S. M. DAVIS, R. S. E. KEEFE, J. K. HSIAO, and J. LIEBERMAN. “Dr. Rosenheck and Colleagues Reply.” American Journal of Psychiatry 164, no. 4 (April 1, 2007): 678–80. https://doi.org/10.1176/appi.ajp.164.4.678-a.
       Full Text
    • Rosenheck, Robert, Marvin Swartz, Joseph McEvoy, T Scott Stroup, Sonia Davis, Richard Se Keefe, John Hsiao, and Jeffrey Lieberman. “Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial.” Expert Rev Pharmacoecon Outcomes Res 7, no. 2 (April 2007): 103–11. https://doi.org/10.1586/14737167.7.2.103.
       Full Text  Link to Item
    • Sullivan, Patrick F., Richard S. E. Keefe, Leslie A. Lange, Ethan M. Lange, T Scott Stroup, Jeffrey Lieberman, and Patricia F. Maness. “NCAM1 and neurocognition in schizophrenia.” Biol Psychiatry 61, no. 7 (April 1, 2007): 902–10. https://doi.org/10.1016/j.biopsych.2006.07.036.
       Full Text  Link to Item
    • Stroup, T Scott, Jeffrey A. Lieberman, Joseph P. McEvoy, Marvin S. Swartz, Sonia M. Davis, George A. Capuano, Robert A. Rosenheck, et al. “Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.” Am J Psychiatry 164, no. 3 (March 2007): 415–27. https://doi.org/10.1176/ajp.2007.164.3.415.
       Full Text  Link to Item
    • Swartz, Marvin S., Diana O. Perkins, T Scott Stroup, Sonia M. Davis, George Capuano, Robert A. Rosenheck, Fred Reimherr, et al. “Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.” Am J Psychiatry 164, no. 3 (March 2007): 428–36. https://doi.org/10.1176/ajp.2007.164.3.428.
       Full Text  Link to Item
    • Pinheiro, Andrea Poyastro, Richard S. E. Keefe, Tara Skelly, Megan Olarte, Keren Leviel, Leslie A. Lange, Ethan M. Lange, T Scott Stroup, Jeffrey Lieberman, and Patrick F. Sullivan. “AKT1 and neurocognition in schizophrenia.” Aust N Z J Psychiatry 41, no. 2 (February 2007): 169–77. https://doi.org/10.1080/00048670601109956.
       Full Text  Link to Item
    • Keefe, Richard S. E. “Cognitive deficits in patients with schizophrenia: effects and treatment.” J Clin Psychiatry 68 Suppl 14 (2007): 8–13.
       Link to Item
    • Rosenheck, R., T. S. Stroup, M. Swartz, J. McEvoy, S. M. Davis, R. S. E. Keefe, J. K. Hsiao, and J. Lieberman. “Dr. Rosenheck and colleagues reply [2].” American Journal of Psychiatry 164, no. 4 (January 1, 2007): 678–80. https://doi.org/10.1176/ajp.2007.164.4.678a.
       Full Text
    • Keefe, Richard S. E., Diana O. Perkins, Hongbin Gu, Robert B. Zipursky, Bruce K. Christensen, and Jeffery A. Lieberman. “A longitudinal study of neurocognitive function in individuals at-risk for psychosis.” Schizophr Res 88, no. 1–3 (December 2006): 26–35. https://doi.org/10.1016/j.schres.2006.06.041.
       Full Text  Link to Item
    • Rosenheck, Robert A., Douglas L. Leslie, Jody Sindelar, Edward A. Miller, Haiqun Lin, T Scott Stroup, Joseph McEvoy, et al. “Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.” Am J Psychiatry 163, no. 12 (December 2006): 2080–89. https://doi.org/10.1176/ajp.2006.163.12.2080.
       Full Text  Link to Item
    • McEvoy, Joseph P., Jackie Johnson, Diana Perkins, Jeffrey A. Lieberman, Robert M. Hamer, Richard S. E. Keefe, Mauricio Tohen, Ira D. Glick, and Tonmoy Sharma. “Insight in first-episode psychosis.” Psychol Med 36, no. 10 (October 2006): 1385–93. https://doi.org/10.1017/S0033291706007793.
       Full Text  Link to Item
    • Keefe, Richard S. E., Robert M. Bilder, Philip D. Harvey, Sonia M. Davis, Barton W. Palmer, James M. Gold, Herbert Y. Meltzer, et al. “Baseline neurocognitive deficits in the CATIE schizophrenia trial.” Neuropsychopharmacology 31, no. 9 (September 2006): 2033–46. https://doi.org/10.1038/sj.npp.1301072.
       Full Text  Link to Item
    • Chakos, Miranda H., Ira D. Glick, Alexander L. Miller, Mark B. Hamner, Del D. Miller, Jayendra K. Patel, Andre Tapp, Richard S. E. Keefe, and Robert A. Rosenheck. “Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial.” Psychiatr Serv 57, no. 8 (August 2006): 1094–1101. https://doi.org/10.1176/ps.2006.57.8.1094.
       Full Text  Link to Item
    • Chwastiak, Lydia A., Robert A. Rosenheck, Joseph P. McEvoy, Richard S. Keefe, Marvin S. Swartz, and Jeffrey A. Lieberman. “Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia.” Psychiatr Serv 57, no. 8 (August 2006): 1102–9. https://doi.org/10.1176/ps.2006.57.8.1102.
       Full Text  Link to Item
    • Keefe, Richard S. E. “Missing the sweet spot disengagement in schizophrenia.” Psychiatry (Edgmont) 3, no. 7 (July 2006): 36–41.
       Link to Item
    • Woodward, Todd S., Mahesh Menon, Xiangen Hu, and Richard S. E. Keefe. “Optimization of a multinomial model for investigating hallucinations and delusions with source monitoring.” Schizophr Res 85, no. 1–3 (July 2006): 106–12. https://doi.org/10.1016/j.schres.2006.03.008.
       Full Text  Link to Item
    • Chwastiak, L. A., R. A. Rosenheck, J. P. McEvoy, R. S. Keefe, M. S. Swartz, and J. A. Lieberman. “Interrelationships of psychiatric symptom severity, medical comorbidity and functional status in patients with schizophrenia.” Journal of General Internal Medicine 21 (April 1, 2006): 76–76.
       Link to Item
    • McEvoy, Joseph P., Jeffrey A. Lieberman, T Scott Stroup, Sonia M. Davis, Herbert Y. Meltzer, Robert A. Rosenheck, Marvin S. Swartz, et al. “Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.” Am J Psychiatry 163, no. 4 (April 2006): 600–610. https://doi.org/10.1176/appi.ajp.163.4.600.
       Full Text  Link to Item
    • Stroup, T Scott, Jeffrey A. Lieberman, Joseph P. McEvoy, Marvin S. Swartz, Sonia M. Davis, Robert A. Rosenheck, Diana O. Perkins, et al. “Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.” Am J Psychiatry 163, no. 4 (April 2006): 611–22. https://doi.org/10.1176/appi.ajp.163.4.611.
       Full Text  Link to Item
    • Keefe, Richard S. E., Margaret Poe, Trina M. Walker, Joseph W. Kang, and Philip D. Harvey. “The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity.” Am J Psychiatry 163, no. 3 (March 2006): 426–32. https://doi.org/10.1176/appi.ajp.163.3.426.
       Full Text  Link to Item
    • LIEBERMAN, JEFFREY A., T S. C. O. T. T. STROUP, JOSEPH P. McEVOY, MARVIN S. SWARTZ, ROBERT A. ROSENHECK, DIANA O. PERKINS, RICHARD S. E. KEEFE, et al. “Dr. Lieberman and Colleagues Reply.” American Journal of Psychiatry 163, no. 3 (March 2006). https://doi.org/10.1176/appi.ajp.163.3.555-a.
       Full Text
    • Lieberman, J. A., T. S. Stroup, J. P. McEvoy, M. S. Swartz, R. A. Rosenheck, D. O. Perkins, R. S. E. Keefe, et al. “Dr. Lieberman and Colleagues reply [17].” American Journal of Psychiatry 163, no. 3 (March 1, 2006): 555–56.
    • Perkins, Diana O., Jacqueline L. Johnson, Robert M. Hamer, Robert B. Zipursky, Richard S. Keefe, Franca Centorrhino, Alan I. Green, et al. “Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.” Schizophr Res 83, no. 1 (March 2006): 53–63. https://doi.org/10.1016/j.schres.2005.10.016.
       Full Text  Link to Item
    • Rosenheck, Robert, Douglas Leslie, Richard Keefe, Joseph McEvoy, Marvin Swartz, Diana Perkins, Scott Stroup, John K. Hsiao, Jeffrey Lieberman, and Jeffrey CATIE Study Investigators Group. “Barriers to employment for people with schizophrenia.” Am J Psychiatry 163, no. 3 (March 2006): 411–17. https://doi.org/10.1176/appi.ajp.163.3.411.
       Full Text  Link to Item
    • Keefe, Richard S. E., Margaret Poe, Trina M. Walker, and Philip D. Harvey. “The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome.” J Clin Exp Neuropsychol 28, no. 2 (February 2006): 260–69. https://doi.org/10.1080/13803390500360539.
       Full Text  Link to Item
    • Keefe, Richard S. E., Larry J. Seidman, Bruce K. Christensen, Robert M. Hamer, Tonmoy Sharma, Margriet M. Sitskoorn, Stephanie L. Rock, et al. “Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis.” Biol Psychiatry 59, no. 2 (January 15, 2006): 97–105. https://doi.org/10.1016/j.biopsych.2005.06.022.
       Full Text  Link to Item
    • Keefe, Richard S. E., Carrie A. Young, Stephanie L. Rock, Scot E. Purdon, James M. Gold, Alan Breier, and Alan HGGN Study Group. “One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.” Schizophr Res 81, no. 1 (January 1, 2006): 1–15. https://doi.org/10.1016/j.schres.2005.07.038.
       Full Text  Link to Item
    • Meyer, Jonathan M., Henry A. Nasrallah, Joseph P. McEvoy, Donald C. Goff, Sonia M. Davis, Miranda Chakos, Jayendra K. Patel, Richard S. E. Keefe, T Scott Stroup, and Jeffrey A. Lieberman. “The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.” Schizophr Res 80, no. 1 (December 1, 2005): 9–18. https://doi.org/10.1016/j.schres.2005.07.015.
       Full Text  Link to Item
    • Miller, Del D., Joseph P. McEvoy, Sonia M. Davis, Stanley N. Caroff, Bruce L. Saltz, Miranda H. Chakos, Marvin S. Swartz, et al. “Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.” Schizophr Res 80, no. 1 (December 1, 2005): 33–43. https://doi.org/10.1016/j.schres.2005.07.034.
       Full Text  Link to Item
    • Narendran, Rajesh, W Gordon Frankle, Richard Keefe, Roberto Gil, Diana Martinez, Mark Slifstein, Lawrence S. Kegeles, et al. “Altered prefrontal dopaminergic function in chronic recreational ketamine users.” Am J Psychiatry 162, no. 12 (December 2005): 2352–59. https://doi.org/10.1176/appi.ajp.162.12.2352.
       Full Text  Link to Item
    • Rosenheck, Robert, Scott Stroup, Richard S. E. Keefe, Joseph McEvoy, Marvin Swartz, Diana Perkins, John Hsiao, Martha Shumway, and Jeffrey Lieberman. “Measuring outcome priorities and preferences in people with schizophrenia.” Br J Psychiatry 187 (December 2005): 529–36. https://doi.org/10.1192/bjp.187.6.529.
       Full Text  Link to Item
    • Stroup, Scott, Paul Appelbaum, Marvin Swartz, Mukesh Patel, Sonia Davis, Dilip Jeste, Scott Kim, et al. “Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial.” Schizophr Res 80, no. 1 (December 1, 2005): 1–8. https://doi.org/10.1016/j.schres.2005.08.007.
       Full Text  Link to Item
    • Strakowski, Stephen M., Jacqueline L. Johnson, Melissa P. Delbello, Robert M. Hamer, Alan I. Green, Mauricio Tohen, Jeffrey A. Lieberman, Ira Glick, Jayendra K. Patel, and Jayendra K. HGDH Research Group. “Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode.” Schizophr Res 78, no. 2–3 (October 15, 2005): 161–69. https://doi.org/10.1016/j.schres.2005.04.017.
       Full Text  Link to Item
    • Lieberman, Jeffrey A., T Scott Stroup, Joseph P. McEvoy, Marvin S. Swartz, Robert A. Rosenheck, Diana O. Perkins, Richard S. E. Keefe, et al. “Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.” N Engl J Med 353, no. 12 (September 22, 2005): 1209–23. https://doi.org/10.1056/NEJMoa051688.
       Full Text  Link to Item
    • Artiola I Fortuny, Lidia, Maite Garolera, David Hermosillo Romo, Esther Feldman, Héctor Fernández Barillas, Richard Keefe, Monique J. Lemaître, et al. “Research with spanish-speaking populations in the United States: lost in the translation. A commentary and a plea.” J Clin Exp Neuropsychol 27, no. 5 (July 2005): 555–64. https://doi.org/10.1080/13803390490918282.
       Full Text  Link to Item
    • Lieberman, Jeffrey A., Gary D. Tollefson, Cecil Charles, Robert Zipursky, Tonmoy Sharma, Rene S. Kahn, Richard S. E. Keefe, et al. “Antipsychotic drug effects on brain morphology in first-episode psychosis.” Arch Gen Psychiatry 62, no. 4 (April 2005): 361–70. https://doi.org/10.1001/archpsyc.62.4.361.
       Full Text  Link to Item
    • Keefe, Richard S. E., Charles E. Eesley, and Margaret P. Poe. “Defining a cognitive function decrement in schizophrenia.” Biol Psychiatry 57, no. 6 (March 15, 2005): 688–91. https://doi.org/10.1016/j.biopsych.2005.01.003.
       Full Text  Link to Item
    • Buchanan, Robert W., Miriam Davis, Donald Goff, Michael F. Green, Richard S. E. Keefe, Andrew C. Leon, Keith H. Nuechterlein, et al. “A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.” Schizophr Bull 31, no. 1 (January 2005): 5–19. https://doi.org/10.1093/schbul/sbi020.
       Full Text  Link to Item
    • Green, Michael F., Keith H. Nuechterlein, James M. Gold, Deanna M. Barch, Jonathan Cohen, Susan Essock, Wayne S. Fenton, et al. “Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.” Biol Psychiatry 56, no. 5 (September 1, 2004): 301–7. https://doi.org/10.1016/j.biopsych.2004.06.023.
       Full Text  Link to Item
    • Keefe, Richard S. E., Larry J. Seidman, Bruce K. Christensen, Robert M. Hamer, Tonmoy Sharma, Margriet M. Sitskoorn, Richard R. J. Lewine, et al. “Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.” Am J Psychiatry 161, no. 6 (June 2004): 985–95. https://doi.org/10.1176/appi.ajp.161.6.985.
       Full Text  Link to Item
    • Keefe, Richard S. E., Terry E. Goldberg, Philip D. Harvey, James M. Gold, Margaret P. Poe, and Leigh Coughenour. “The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery.” Schizophr Res 68, no. 2–3 (June 1, 2004): 283–97. https://doi.org/10.1016/j.schres.2003.09.011.
       Full Text  Link to Item
    • Hawkins, K. A., J. Addington, R. S. E. Keefe, B. Christensen, D. O. Perkins, R. Zipurksy, S. W. Woods, et al. “Neuropsychological status of subjects at high risk for a first episode of psychosis.” Schizophr Res 67, no. 2–3 (April 1, 2004): 115–22. https://doi.org/10.1016/j.schres.2003.08.007.
       Full Text  Link to Item
    • Harvey, Philip D., Michael F. Green, Richard S. E. Keefe, and Dawn I. Velligan. “Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness.” J Clin Psychiatry 65, no. 3 (March 2004): 361–72.
       Link to Item
    • Keefe, Richard S. E., Margaret P. Poe, Joseph P. McEvoy, and Adam Vaughan. “Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications.” Psychopharmacology (Berl) 169, no. 3–4 (September 2003): 383–89. https://doi.org/10.1007/s00213-003-1476-0.
       Full Text  Link to Item
    • Keefe, Richard S. E., Richard C. Mohs, Robert M. Bilder, Philip D. Harvey, Michael F. Green, Herbert Y. Meltzer, James M. Gold, and Mary Sano. “Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale.” Schizophr Bull 29, no. 1 (2003): 45–55. https://doi.org/10.1093/oxfordjournals.schbul.a006990.
       Full Text  Link to Item
    • Keefe, R. S. E. “[The evaluation of cognitive dysfunctions in schizophrenia].” Encephale 28 Spec No 2 Pt 2 (September 2002): S11–13.
       Link to Item
    • Keefe, Richard S. E., Miriam C. Arnold, Ute J. Bayen, Joseph P. McEvoy, and William H. Wilson. “Source-monitoring deficits for self-generated stimuli in schizophrenia: multinomial modeling of data from three sources.” Schizophr Res 57, no. 1 (September 1, 2002): 51–67. https://doi.org/10.1016/s0920-9964(01)00306-1.
       Full Text  Link to Item
    • Conway, Charles R., Anna M. Bollini, Brevick G. Graham, Richard S. E. Keefe, Susan S. Schiffman, and Joseph P. McEvoy. “Sensory acuity and reasoning in delusional disorder.” Compr Psychiatry 43, no. 3 (May 2002): 175–78. https://doi.org/10.1053/comp.2002.32358.
       Full Text  Link to Item
    • Harvey, P. D., and R. S. Keefe. “Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment.” Am J Psychiatry 158, no. 2 (February 2001): 176–84. https://doi.org/10.1176/appi.ajp.158.2.176.
       Full Text  Link to Item
    • Bollini, A. M., M. C. Arnold, and R. S. Keefe. “Test-retest reliability of the dot test of visuospatial working memory in patients with schizophrenia and controls.” Schizophr Res 45, no. 1–2 (September 29, 2000): 169–73. https://doi.org/10.1016/s0920-9964(99)00216-9.
       Full Text  Link to Item
    • Roitman, S. E., V. Mitropoulou, R. S. Keefe, J. M. Silverman, M. Serby, P. D. Harvey, D. A. Reynolds, R. C. Mohs, and L. J. Siever. “Visuospatial working memory in schizotypal personality disorder patients.” Schizophr Res 41, no. 3 (February 14, 2000): 447–55. https://doi.org/10.1016/s0920-9964(99)00085-7.
       Full Text  Link to Item
    • Keefe, R. S., M. C. Arnold, U. J. Bayen, and P. D. Harvey. “Source monitoring deficits in patients with schizophrenia; a multinomial modelling analysis.” Psychol Med 29, no. 4 (July 1999): 903–14. https://doi.org/10.1017/s0033291799008673.
       Full Text  Link to Item
    • Keefe, R. S. E., A. M. Bollini, and S. G. Silva. “Do novel antipsychotics improve cognition? A report of a meta-analysis.” Psychiatric Annals 29, no. 11 (January 1, 1999): 623–29. https://doi.org/10.3928/0048-5713-19991101-08.
       Full Text
    • Keefe, R. S., S. G. Silva, D. O. Perkins, and J. A. Lieberman. “The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.” Schizophr Bull 25, no. 2 (1999): 201–22. https://doi.org/10.1093/oxfordjournals.schbul.a033374.
       Full Text  Link to Item
    • Davis, K. L., M. S. Buchsbaum, L. Shihabuddin, J. Spiegel-Cohen, M. Metzger, E. Frecska, R. S. Keefe, and P. Powchik. “Ventricular enlargement in poor-outcome schizophrenia.” Biol Psychiatry 43, no. 11 (June 1, 1998): 783–93. https://doi.org/10.1016/s0006-3223(97)00553-2.
       Full Text  Link to Item
    • Keefe, R. S. E., M. Courtney, U. J. Bayan, P. D. Harvey, and J. M. McEvoy. “Does autonoetic agnosia underlie specific psychotic symptoms in schizophrenia?” Schizophrenia Research 29, no. 1–2 (January 1998): 36–36. https://doi.org/10.1016/s0920-9964(97)88379-x.
       Full Text
    • Vocisano, C., D. N. Klein, and R. S. Keefe. “Lifetime comorbidity, lifetime history of psychosis and suicide attempts, and current symptoms of patients with deteriorated affective disorder.” Psychiatry Res 73, no. 1–2 (November 14, 1997): 33–45. https://doi.org/10.1016/s0165-1781(97)00114-5.
       Full Text  Link to Item
    • Roitman, S. E., R. S. Keefe, P. D. Harvey, L. J. Siever, and R. C. Mohs. “Attentional and eye tracking deficits correlate with negative symptoms in schizophrenia.” Schizophr Res 26, no. 2–3 (August 29, 1997): 139–46. https://doi.org/10.1016/s0920-9964(97)00044-3.
       Full Text  Link to Item
    • Keefe, R. S., S. E. Lees-Roitman, and R. L. Dupre. “Performance of patients with schizophrenia on a pen and paper visuospatial working memory task with short delay.” Schizophr Res 26, no. 1 (July 25, 1997): 9–14. https://doi.org/10.1016/S0920-9964(97)00037-6.
       Full Text  Link to Item
    • Roitman, S. E., B. A. Cornblatt, A. Bergman, M. Obuchowski, V. Mitropoulou, R. S. Keefe, J. M. Silverman, and L. J. Siever. “Attentional functioning in schizotypal personality disorder.” Am J Psychiatry 154, no. 5 (May 1997): 655–60. https://doi.org/10.1176/ajp.154.5.655.
       Full Text  Link to Item
    • Keefe, R. S., J. M. Silverman, R. C. Mohs, L. J. Siever, P. D. Harvey, L. Friedman, S. E. Roitman, et al. “Eye tracking, attention, and schizotypal symptoms in nonpsychotic relatives of patients with schizophrenia.” Arch Gen Psychiatry 54, no. 2 (February 1997): 169–76. https://doi.org/10.1001/archpsyc.1997.01830140081014.
       Full Text  Link to Item
    • Harvey, P. D., and R. S. E. Keefe. “Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment.” Cns Spectrums 2, no. 8 (January 1, 1997): 41–55. https://doi.org/10.1017/S1092852900005034.
       Full Text
    • Harvey, P. D., and R. S. E. Keefe. “Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment.” Cns Spectrums 2, no. 8 (1997): 41–55.
    • Keefe, Richard S. E., Miriam Courtney, and Joseph M. McEvoy. “Self-monitoring deficits in schizophrenia: Autonoetic agnosia.” Schizophrenia Research 24, no. 1–2 (January 1997): 110–110. https://doi.org/10.1016/s0920-9964(97)82306-7.
       Full Text
    • Harvey, P. D., M. Davidson, L. White, R. S. Keefe, J. Hirschowitz, R. C. Mohs, and K. L. Davis. “Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.” Biol Psychiatry 40, no. 8 (October 15, 1996): 755–60. https://doi.org/10.1016/0006-3223(95)00486-6.
       Full Text  Link to Item
    • Keefe, R. S. E., and B. A. Cornblatt. “The neuropsychology of schizophrenia - David,AS, Cutting,JC.” Contemporary Psychology 41, no. 9 (September 1, 1996): 900–902.
       Link to Item
    • Keefe, R. S., E. Frescka, S. H. Apter, M. Davidson, J. M. Macaluso, J. Hirschowitz, and K. L. Davis. “Clinical characteristics of Kraepelinian schizophrenia: replication and extension of previous findings.” Am J Psychiatry 153, no. 6 (June 1996): 806–11. https://doi.org/10.1176/ajp.153.6.806.
       Full Text  Link to Item
    • Epstein, J. I., R. S. Keefe, S. L. Roitman, P. D. Harvey, and R. C. Mohs. “Impact of neuroleptic medications on continuous performance test measures in schizophrenia.” Biol Psychiatry 39, no. 10 (May 15, 1996): 902–5. https://doi.org/10.1016/0006-3223(95)00588-9.
       Full Text  Link to Item
    • Siegel, B. V., R. L. Trestman, S. O’Flaithbheartaigh, V. Mitropoulou, F. Amin, R. Kirrane, J. Silverman, J. Schmeidler, R. S. Keefe, and L. J. Siever. “D-amphetamine challenge effects on Wisconsin Card Sort Test. Performance in schizotypal personality disorder.” Schizophr Res 20, no. 1–2 (May 1996): 29–32. https://doi.org/10.1016/0920-9964(95)00002-x.
       Full Text  Link to Item
    • Harvey, P. D., R. S. E. Keefe, V. Mitroupolou, R. DuPre, S. L. Roitman, R. C. Mohs, and L. J. Siever. “Information-processing markers of vulnerability to schizophrenia: Performance of patients with schizotypal and nonschizotypal personality disorders.” Psychiatry Research 60, no. 1 (February 28, 1996): 49–56. https://doi.org/10.1016/0165-1781(95)02764-5.
       Full Text
    • Vocisano, C., D. N. Klein, R. S. Keefe, E. R. Dienst, and M. M. Kincaid. “Demographics, family history, premorbid functioning, developmental characteristics, and course of patients with deteriorated affective disorder.” Am J Psychiatry 153, no. 2 (February 1996): 248–55. https://doi.org/10.1176/ajp.153.2.248.
       Full Text  Link to Item
    • Trestman, R. L., R. S. Keefe, V. Mitropoulou, P. D. Harvey, M. L. deVegvar, S. Lees-Roitman, M. Davidson, A. Aronson, J. Silverman, and L. J. Siever. “Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder.” Psychiatry Res 59, no. 1–2 (November 29, 1995): 127–36. https://doi.org/10.1016/0165-1781(95)02709-2.
       Full Text  Link to Item
    • Davidson, M., and R. S. Keefe. “Cognitive impairment as a target for pharmacological treatment in schizophrenia.” Schizophr Res 17, no. 1 (September 1995): 123–29. https://doi.org/10.1016/0920-9964(95)00037-m.
       Full Text  Link to Item
    • Keefe, R. S., S. E. Roitman, P. D. Harvey, C. S. Blum, R. L. DuPre, D. M. Prieto, M. Davidson, and K. L. Davis. “A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia.” Schizophr Res 17, no. 1 (September 1995): 25–33. https://doi.org/10.1016/0920-9964(95)00027-j.
       Full Text  Link to Item
    • Keefe, Richard S. E., Sonia Lees Roitman, Rachel L. Dupre, Philip D. Harvey, Kenneth L. Davis, and Richard C. Mohs. “The relationship between working memory deficits and other measures sensitive to prefrontal dysfunction.” Schizophrenia Research 15, no. 1–2 (April 1995): 123–123. https://doi.org/10.1016/0920-9964(95)95378-m.
       Full Text
    • Davidson, M., P. D. Harvey, P. Powchik, M. Parrella, L. White, H. Y. Knobler, M. F. Losonczy, R. S. Keefe, S. Katz, and E. Frecska. “Severity of symptoms in chronically institutionalized geriatric schizophrenic patients.” Am J Psychiatry 152, no. 2 (February 1995): 197–207. https://doi.org/10.1176/ajp.152.2.197.
       Full Text  Link to Item
    • Yehuda, R., R. S. Keefe, P. D. Harvey, R. A. Levengood, D. K. Gerber, J. Geni, and L. J. Siever. “Learning and memory in combat veterans with posttraumatic stress disorder.” Am J Psychiatry 152, no. 1 (January 1995): 137–39. https://doi.org/10.1176/ajp.152.1.137.
       Full Text  Link to Item
    • Keefe, R. S. “The contribution of neuropsychology to psychiatry.” Am J Psychiatry 152, no. 1 (January 1995): 6–15. https://doi.org/10.1176/ajp.152.1.6.
       Full Text  Link to Item
    • Siever, L. J., L. Friedman, J. Moskowitz, V. Mitropoulou, R. Keefe, S. L. Roitman, D. Merhige, R. Trestman, J. Silverman, and R. Mohs. “Eye movement impairment and schizotypal psychopathology.” Am J Psychiatry 151, no. 8 (August 1994): 1209–15. https://doi.org/10.1176/ajp.151.8.1209.
       Full Text  Link to Item
    • Keefe, R. S., J. M. Silverman, S. E. Roitman, P. D. Harvey, M. A. Duncan, D. Alroy, L. J. Siever, K. L. Davis, and R. C. Mohs. “Performance of nonpsychotic relatives of schizophrenic patients on cognitive tests.” Psychiatry Res 53, no. 1 (July 1994): 1–12. https://doi.org/10.1016/0165-1781(94)90091-4.
       Full Text  Link to Item
    • Apter, S. H., R. S. E. Keefe, J. Hirschowitz, M. Davidson, J. M. Macaluso, R. Amato, and K. L. Davis. “Longitudinal classification in schizophrenia: The relationship between kraepelinian and deficit syndrome subtypologies.” Biological Psychiatry 35, no. 9 (May 1994): 695–695. https://doi.org/10.1016/0006-3223(94)90944-x.
       Full Text
    • Epstein, J. I., R. S. E. Keefe, S. E. Lees Roitman, P. D. Harvey, M. Davidson, L. J. Siever, and R. C. Mohs. “Neuroleptic effects on CPT and eye tracking in schizophrenia.” Biological Psychiatry 35, no. 9 (May 1994): 674–674. https://doi.org/10.1016/0006-3223(94)90872-9.
       Full Text
    • Frecska, E., M. F. Losonczy, R. S. E. Keefe, S. Apter, M. Davidson, R. C. Mohs, and K. L. Davis. “Age dependent change of ventricular measures in schizophrenia: Cross-sectional analysis.” Biological Psychiatry 35, no. 9 (May 1994): 704–5. https://doi.org/10.1016/0006-3223(94)90980-6.
       Full Text
    • Keefe, R. S. E., C. Blum, S. L. Roitman, P. D. Harvey, M. Davidson, R. C. Mohs, and K. L. Davis. “Working memory dysfunction in Kraepelinian schizophrenics.” Biological Psychiatry 35, no. 9 (May 1994): 660–660. https://doi.org/10.1016/0006-3223(94)90820-6.
       Full Text
    • Kahn, R. S., P. D. Harvey, M. Davidson, R. S. Keefe, S. Apter, J. M. Neale, R. C. Mohs, and K. L. Davis. “Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function.” Schizophr Res 11, no. 3 (February 1994): 217–24. https://doi.org/10.1016/0920-9964(94)90015-9.
       Full Text  Link to Item
    • Siever, L. J., O. F. Kalus, and R. S. Keefe. “The boundaries of schizophrenia.” Psychiatr Clin North Am 16, no. 2 (June 1993): 217–44.
       Link to Item
    • Frecska, E., M. F. Losonczy, R. S. E. Keefe, J. M. Silverman, M. Davidson, and K. L. Davis. “The characteristics of poor outcome, 'Kraepelinian' schizophrenia.” European Neuropsychopharmacology 3, no. 3 (January 1, 1993): 400. https://doi.org/10.1016/0924-977X(93)90193-P.
       Full Text
    • Harvey, P. D., M. F. Lenzenweger, R. S. Keefe, D. L. Pogge, M. R. Serper, and R. C. Mohs. “Empirical assessment of the factorial structure of clinical symptoms in schizophrenic patients: formal thought disorder.” Psychiatry Res 44, no. 2 (November 1992): 141–51. https://doi.org/10.1016/0165-1781(92)90048-8.
       Full Text  Link to Item
    • Keefe, R. S., P. D. Harvey, M. F. Lenzenweger, M. Davidson, S. H. Apter, J. Schmeidler, R. C. Mohs, and K. L. Davis. “Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: negative symptoms.” Psychiatry Res 44, no. 2 (November 1992): 153–65. https://doi.org/10.1016/0165-1781(92)90049-9.
       Full Text  Link to Item
    • Davidson, M., R. S. Kahn, R. G. Stern, P. D. Harvey, R. Keefe, P. Knott, S. Apter, L. Webster, and K. L. Davis. “Measurements of plasma homovanillic acid in schizophrenic patients.” Clin Neuropharmacol 15 Suppl 1 Pt A (1992): 521A-522A. https://doi.org/10.1097/00002826-199201001-00271.
       Full Text  Link to Item
    • Harvey, P. D., R. S. Kahn, M. Davidson, R. C. Mohs, R. S. E. Keefe, and K. L. Davis. “Dopaminergic correlates of attentional performance in unmedicated schizophrenic patients.” Schizophrenia Research 6, no. 2 (January 1992): 136–136. https://doi.org/10.1016/0920-9964(92)90194-a.
       Full Text
    • Keefe, R. S. E., J. M. Silverman, F. Amin, S. E. Lees, A. Duncan, P. D. Harvey, M. Davidson, L. J. Siever, R. C. Mohs, and K. L. Davis. “Frontal functioning and plasma HVA in the relatives of schizophrenic patients.” Schizophrenia Research 6, no. 2 (January 1992): 158–158. https://doi.org/10.1016/0920-9964(92)90244-y.
       Full Text
    • CORNBLATT, B. A., and R. S. E. KEEFE. “THE GENETICS OF MENTAL-ILLNESS - AN OVERVIEW.” Social Biology 38, no. 3–4 (September 1, 1991): R1–5.
       Link to Item
    • Harvey, P. D., K. M. Putnam, M. Davidson, R. S. Kahn, P. Powchik, R. McQueeney, R. S. Keefe, and K. L. Davis. “Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients.” Psychiatry Res 38, no. 3 (September 1991): 285–92. https://doi.org/10.1016/0165-1781(91)90018-k.
       Full Text  Link to Item
    • Thaker, G., M. Moran, S. Cassady, H. Adami, and C. Tamminga. “Normal smooth pursuit eye movements in volunteer subjects meeting schizotypal personality disorder criteria.” Am J Psychiatry 148, no. 8 (August 1991): 1096–97.
       Link to Item
    • Frecska, E., M. Losonczy, R. S. E. Keefe, J. M. Silverman, M. Davidson, P. Harvey, R. T. McQueeney, D. Lobel, S. Apter, and K. L. Davis. “Kraepelinian schizophrenia: A replication in an independent sample.” Schizophrenia Research 4, no. 3 (May 1991): 257–257. https://doi.org/10.1016/0920-9964(91)90108-4.
       Full Text
    • Harvey, P. D., M. Davidson, R. C. Mohs, R. S. E. Keefe, J. Moskowitz, P. Knott, and M. Duffelmeyer. “Plasma HVA correlates of attentional performance in unmedicated schizophrenics.” Schizophrenia Research 4, no. 3 (May 1991): 345–46. https://doi.org/10.1016/0920-9964(91)90258-s.
       Full Text
    • Keefe, R. S., D. S. Lobel, R. C. Mohs, J. M. Silverman, P. D. Harvey, M. Davidson, M. F. Losonczy, and K. L. Davis. “Diagnostic issues in chronic schizophrenia: kraepelinian schizophrenia, undifferentiated schizophrenia, and state-independent negative symptoms.” Schizophr Res 4, no. 2 (March 1991): 71–79. https://doi.org/10.1016/0920-9964(91)90026-n.
       Full Text  Link to Item
    • Harvey, P. D., R. S. Keefe, J. Moskowitz, K. M. Putnam, R. C. Mohs, and K. L. Davis. “Attentional markers of vulnerability to schizophrenia: performance of medicated and unmedicated patients and normals.” Psychiatry Res 33, no. 2 (August 1990): 179–88. https://doi.org/10.1016/0165-1781(90)90072-d.
       Full Text  Link to Item
    • Siever, L. J., J. M. Silverman, T. B. Horvath, H. Klar, E. Coccaro, R. S. Keefe, L. Pinkham, P. Rinaldi, R. C. Mohs, and K. L. Davis. “Increased morbid risk for schizophrenia-related disorders in relatives of schizotypal personality disordered patients.” Arch Gen Psychiatry 47, no. 7 (July 1990): 634–40. https://doi.org/10.1001/archpsyc.1990.01810190034005.
       Full Text  Link to Item
    • Siever, L. J., R. Keefe, D. P. Bernstein, E. F. Coccaro, H. M. Klar, Z. Zemishlany, A. E. Peterson, M. Davidson, T. Mahon, and T. Horvath. “Eye tracking impairment in clinically identified patients with schizotypal personality disorder.” Am J Psychiatry 147, no. 6 (June 1990): 740–45. https://doi.org/10.1176/ajp.147.6.740.
       Full Text  Link to Item
    • Keefe, R. S., R. C. Mohs, M. F. Losonczy, M. Davidson, J. M. Silverman, T. B. Horvath, and K. L. Davis. “Premorbid sociosexual functioning and long-term outcome in schizophrenia.” Am J Psychiatry 146, no. 2 (February 1989): 206–11. https://doi.org/10.1176/ajp.146.2.206.
       Full Text  Link to Item
    • Keefe, R. S., L. J. Siever, R. C. Mohs, A. E. Peterson, T. R. Mahon, R. L. Bergman, and K. L. Davis. “Eye tracking, schizophrenic symptoms, and schizotypal personality disorder.” Eur Arch Psychiatry Neurol Sci 239, no. 1 (1989): 39–42. https://doi.org/10.1007/BF01739742.
       Full Text  Link to Item
    • Silverman, J. M., R. S. Keefe, R. C. Mohs, and K. L. Davis. “A study of the reliability of the family history method in genetic studies of Alzheimer disease.” Alzheimer Dis Assoc Disord 3, no. 4 (1989): 218–23.
       Link to Item
    • Keefe, R. S., R. C. Mohs, M. Davidson, M. F. Losonczy, J. M. Silverman, J. C. Lesser, T. B. Horvath, and K. L. Davis. “Kraepelinian schizophrenia: a subgroup of schizophrenia?” Psychopharmacol Bull 24, no. 1 (1988): 56–61.
       Link to Item
    • Silverman, J. M., R. C. Mohs, M. Davidson, M. F. Losonczy, R. S. Keefe, J. C. Breitner, J. E. Sorokin, and K. L. Davis. “Familial schizophrenia and treatment response.” Am J Psychiatry 144, no. 10 (October 1987): 1271–76. https://doi.org/10.1176/ajp.144.10.1271.
       Full Text  Link to Item
    • Davidson, M., R. S. Keefe, R. C. Mohs, L. J. Siever, M. F. Losonczy, T. B. Horvath, and K. L. Davis. “L-dopa challenge and relapse in schizophrenia.” Am J Psychiatry 144, no. 7 (July 1987): 934–38. https://doi.org/10.1176/ajp.144.7.934.
       Full Text  Link to Item
    • Keefe, R. S., R. C. Mohs, M. F. Losonczy, M. Davidson, J. M. Silverman, K. S. Kendler, T. B. Horvath, R. Nora, and K. L. Davis. “Characteristics of very poor outcome schizophrenia.” Am J Psychiatry 144, no. 7 (July 1987): 889–95. https://doi.org/10.1176/ajp.144.7.889.
       Full Text  Link to Item
    • Keefe, R. S., J. M. Silverman, L. J. Siever, and B. A. Cornblatt. “Refining phenotype characterization in genetic linkage studies of schizophrenia.” Soc Biol 38, no. 3–4 (n.d.): 197–218. https://doi.org/10.1080/19485565.1991.9988788.
       Full Text  Link to Item
    • Keefe, Richard S. E., Philip D. Harvey, Anzalee Khan, Jay B. Saoud, Corinne Staner, Michael Davidson, and Remy Luthringer. “Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms: Results From a Randomized Controlled Trial.” J Clin Psychiatry 79, no. 3 (n.d.). https://doi.org/10.4088/JCP.17m11753.
       Full Text  Link to Item

  • Book Sections

    • Vance, M., E. Pappadopulos, R. Keefe, and A. Kalali. “Conceptual issues in cultural adaptation and the role of culture in assessment of health-related quality of life in schizophrenia.” In Beyond Assessment of Quality of Life in Schizophrenia, 53–62, 2016. https://doi.org/10.1007/978-3-319-30061-0_4.
       Full Text

  • Conference Papers

    • Brown, David, Kazuyuki Nakagome, Joachim Cordes, Ronald Brenner, Gerhard Gründer, Richard S. E. Keefe, Robert Riesenberg, et al. “Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.” In Schizophr Bull, 45:350–59, 2019. https://doi.org/10.1093/schbul/sby049.
       Full Text  Link to Item
    • Eum, Seenae, S Kristian Hill, Leah H. Rubin, Ryan M. Carnahan, James L. Reilly, Elena I. Ivleva, Sarah K. Keedy, et al. “Cognitive burden of anticholinergic medications in psychotic disorders.” In Schizophr Res, 190:129–35, 2017. https://doi.org/10.1016/j.schres.2017.03.034.
       Full Text  Link to Item
    • Graham, K. A., R. S. Keefe, J. A. Lieberman, A. S. Calikoglu, K. M. Lansing, and D. O. Perkins. “Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia.” In Early Interv Psychiatry, 9:397–405, 2015. https://doi.org/10.1111/eip.12122.
       Full Text  Link to Item
    • Cella, Matteo, Daniel Stahl, Sarah Morris, Richard Keefe, Morris David Bell, Robea Heinssen, and Til Wykes. “EFFECTS OF COGNITIVE REMEDIATION ON NEGATIVE SYMPTOMS DIMENSIONS: EXPLORING THE ROLE OF WORKING MEMORY.” In Schizophrenia Bulletin, 41:S40–41. OXFORD UNIV PRESS, 2015.
       Link to Item
    • Keefe, R. S. E., A. R. Mahableshwarkar, and C. K. Olsen. “P.2.f.013 Clinical evidence for improvement in cognitive dysfunction in patients with major depressive disorder (MDD) after treatment with vortioxetine.” In European Neuropsychopharmacology, 23:S402–3. Elsevier BV, 2013. https://doi.org/10.1016/s0924-977x(13)70636-9.
       Full Text
    • Madhoo, M., R. M. Roth, R. S. E. Keefe, A. Sambunaris, B. Scheckner, J. Nielsen, B. Adeyi, J. Wu, and R. Lasser. “P.2.a.017 Lisdexamfetamine dimesylate augmentation effects on executive function in major depressive disorder based on depressive symptom levels.” In European Neuropsychopharmacology, 22:S233–34. Elsevier BV, 2012. https://doi.org/10.1016/s0924-977x(12)70346-2.
       Full Text
    • Madhoo, M., R. S. E. Keefe, R. M. Roth, A. Sambunaris, J. Wu, M. H. Trivedi, C. S. Anderson, and R. Lasser. “Efficacy and safety of lisdexamfetamine dimesylate in adults with executive dysfunction and partial or full remission of major depressive disorder.” In International Journal of Neuropsychopharmacology, 15:189–189. OXFORD UNIV PRESS, 2012.
       Link to Item
    • Supina, D., J. Endicott, M. Madhoo, R. S. E. Keefe, M. Trivedi, J. Wu, B. Scheckner, and R. Lasser. “PMH61 Effects of Lisdexamfetamine Dimesylate Augmentation on Functional Outcomes in Adults with Partially or Fully Remitted Major Depressive Disorder.” In Value in Health, 15:A93–A93. Elsevier BV, 2012. https://doi.org/10.1016/j.jval.2012.03.506.
       Full Text
    • Jarskog, F Fredrik, Richard A. Grove, Joseph P. McEvoy, Richard S. E. Keefe, Martin T. Lowy, Joseph P. Horrigan, and Margaret A. Peykamian. “Randomized, Double-Blind, Placebo Controlled, Parallel Group Exploratory Study of GSK239512 for Cognitive Impairment in Stable Schizophrenia Subjects on Background Antipsychotic Therapy.” In Biological Psychiatry, 71:63S-64S. ELSEVIER SCIENCE INC, 2012.
       Link to Item
    • Colijn, Mark A., Mariapaola Barbato, Richard S. E. Keefe, Diana O. Perkins, Scott W. Woods, and Jean Addington. “Poster #143 AT RISK FOR PSYCHOSIS: THE ROLE OF COGNITION.” In Schizophrenia Research, 136:S237–S237. Elsevier BV, 2012. https://doi.org/10.1016/s0920-9964(12)70715-6.
       Full Text
    • Keefe, Richard S. E., Robert W. Buchanan, Stephen R. Marder, Nina R. Schooler, Ashish Dugar, Milana Zivkov, and Michelle Stewart. “Poster #199 CLINICAL TRIALS OF POTENTIAL COGNITIVE-ENHANCING DRUGS IN SCHIZOPHRENIA: WHAT HAVE WE LEARNED SO FAR?” In Schizophrenia Research, 136:S352–S352. Elsevier BV, 2012. https://doi.org/10.1016/s0920-9964(12)71031-9.
       Full Text
    • Uchida, Hiroyuki, Hitoshi Sakurai, Robert R. Bies, Scott Stroup, Richard S. E. Keefe, Takefumi Suzuki, Takashi Tsuboi, Masaru Mimura, Bruce G. Pollock, and David C. Mamo. “DOPAMINE D2 RECEPTOR OCCUPANCY AND COGNITION IN SCHIZOPHRENIA: ANALYSIS OF THE CATIE DATA.” In Schizophrenia Research, 136:S359–S359. ELSEVIER SCIENCE BV, 2012.
       Link to Item
    • Sarkisyan, G., I. Gurovich, and R. S. E. Keefe. “NORMATIVE DATA FOR RUSSIAN POPULATION AND STANDARDIZATION OF THE SCALE "BRIEF ASSESSMENT OF COGNITION IN SCHIZOPHRENIA".” In European Psychiatry, Vol. 26. ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2011.
       Link to Item
    • Reichenberg, Abraham, Avshalom Caspi, HonaLee Harrington, Renate Houts, Richard S. Keefe, Robin M. Murray, Richie Poulton, and Terrie E. Moffitt. “Static and Dynamic Cognitive Deficits in Childhood Precede Adult Schizophrenia: A 30-Year Study.” In Biological Psychiatry, 67:12S-12S. ELSEVIER SCIENCE INC, 2010.
       Link to Item
    • Kern, Robert S., James M. Gold, Dwight Dickinson, Michael F. Green, Keith H. Nuechterlein, Richard S. E. Keefe, Stephen R. Marder, and Catherine A. Sugar. “COGNITIVE DYSFUNCTION AND COMMUNITY FUNCTIONING IN SCHIZOPHRENIA: RESULTS FROM THE MATRICS PSYCHOMETRIC AND STANDARDIZATION STUDY (PASS).” In Schizophrenia Research, 117:323–24. Elsevier BV, 2010. https://doi.org/10.1016/j.schres.2010.02.551.
       Full Text
    • Reichenberg, Abraham, Avshalom Caspi, HonaLee Harrington, Renate Houts, Richard Keefe, Robin Murray, Richie Poulton, and Terrie Moffitt. “STATIC AND DYNAMIC COGNITIVE DEFICITS IN CHILDHOOD PRECEDE ADULT SCHIZOPHRENIA: A 30-YEAR STUDY.” In Schizophrenia Research, 117:175–175. Elsevier BV, 2010. https://doi.org/10.1016/j.schres.2010.02.207.
       Full Text
    • Keefe, Richard S. E., and Wayne S. Fenton. “HOW SHOULD DSM-V CRITERIA FOR SCHIZOPHRENIA INCLUDE COGNITIVE IMPAIRMENT?” In Deconstructing Psychosis: Refining the Research Agenda for Dsm V, edited by C. A. Tamminga, P. J. Sirovatka, D. A. Regier, and J. VanOs, 83–98. AMER PSYCHIATRIC PRESS, INC, 2010.
       Link to Item
    • Javitt, Daniel C., R. W. Buchanan, J. A. Lieberman, R. S. Keefe, and S. R. Marder. “EVALUATION OF THE EFFECTS OF AL-108 ON NEUROCOGNITION IN SCHIZOPHRENIA: INITIAL TURNS STUDY RESULTS.” In Schizophrenia Bulletin, 35:365–66, 2009.
       Link to Item
    • Ventura, Joseph, R. M. Bilder, S. R. Reise, and R. S. Keefe. “DEVELOPMENT OF AN INTERVIEW-BASED "CO-PRIMARY'' MEASURE OF COGNITION.” In Schizophrenia Bulletin, 35:21–22, 2009.
       Link to Item
    • Keefe, Richard S. E. “Increasing sensitivity of early detection of psychosis with cognitive measures.” In International Journal of Psychiatry in Clinical Practice, 13:7–7. TAYLOR & FRANCIS AS, 2009.
       Link to Item
    • Keefe, R. S. E., P. D. Harvey, T. E. Goldberg, J. M. Gold, and T. M. Walker. “General and specific cognitive deficits in bipolar depression: the Brief Assessment of Cognition in Affective Disorders (BAC-A).” In Bipolar Disorders, 9:9–9. BLACKWELL PUBLISHING, 2007.
       Link to Item
    • Marx, Christine E., Richard S. Keefe, Linda A. Leimone, Robert M. Hamer, Daniel W. Bradford, Lawrence Dunn, Victoria M. Payne, et al. “Proof-of-concept trial with the neurosterold pregnenolone targeting neurocognitive and negative symptoms in schizophrenia.” In Biological Psychiatry, 61:13S-13S. ELSEVIER SCIENCE INC, 2007.
       Link to Item
    • Nasrallah, Henry A., Richard S. E. Keefe, Sonia Davis, Joseph Mcevoy, Don Goff, Jonathan Meyer, T Scott Stroup, and Jeffrey A. Lieberman. “Cognitive improvement correlates with weight gain in schizophrenia subjects receiving quetiapine but not other antipsychotics: Data from the CATIE trial.” In Biological Psychiatry, 61:247S-248S. ELSEVIER SCIENCE INC, 2007.
       Link to Item
    • Bratti, I., S. R. Marder, R. S. Keefe, and R. M. Bilder. “A brief cognitive assessment tool for schizophrenia (B-CATS): Scale construction.” In Schizophrenia Bulletin, 33:584–584, 2007.
       Link to Item
    • Hill, S. K., J. A. Sweeney, R. M. Hamer, R. S. Keefe, D. O. Perkins, H. Gu, G. Koch, J. P. McEvoy, and J. A. Lieberman. “Efficiency of the BACS and CATIE neuropsychological batteries in assessing cognition and antipsychotic treatment related change in cognition during the CAFE clinical trial.” In Schizophrenia Bulletin, 33:561–561, 2007.
       Link to Item
    • Keefe, Richard, Robert M. Bilder, Sonia M. Davis, Philip D. Harvey, Barton W. Palmer, James M. Gold, Herbert Y. Meltzer, et al. “Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial.” In Neuropsychopharmacology, 31:S244–45. NATURE PUBLISHING GROUP, 2006.
       Link to Item
    • Keefe, R. S. E. “Measures of cognitive change in schizophrenia clinical trials.” In International Journal of Neuropsychopharmacology, 9:S48–S48. CAMBRIDGE UNIV PRESS, 2006.
       Link to Item
    • Keefe, R. S. E., G. U. Hongbin, J. A. Sweeney, D. O. Perkins, J. P. McEvoy, R. M. Hamer, and J. A. Lieberman. “The effects of olanzapine, quetiapine, and risperidone on neurocognitive function in first-episode psychosis: A double-blind, 52-week comparison.” In Biological Psychiatry, 59:231S-232S. ELSEVIER SCIENCE INC, 2006.
       Link to Item
    • Keefe, R. S. E., H. Gu, D. Perkins, R. M. Hamer, and J. A. Lieberman. “The effects of olanzapine, quetiapine, and risperidone on neurocognitive function in first-episode psychosis: A double-blind, 52-week comparison.” In Schizophrenia Research, 81:54–54. ELSEVIER SCIENCE BV, 2006.
       Link to Item
    • Lieberman, J. A., T. S. Stroup, J. P. McEvoy, M. S. Swartz, R. A. Rosenheck, D. O. Perkins, R. S. Keefe, et al. “Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: Primary efficacy and safety outcomes of the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial.” In Neuropsychopharmacology, 30:S32–S32, 2005.
       Link to Item
    • Perkins, D., H. B. Gu, R. B. Zipursky, B. K. Christensen, V. Dixon, and R. S. Keefe. “Neurocognitive function in individuals "at-risk" for psychosis.” In Neuropsychopharmacology, 29:S220–S220, 2004.
       Link to Item
    • Sethuraman, G., S. Ahmed, S. L. Rock, C. A. Young, E. M. Marquez, S. E. Purdon, and R. S. E. Keefe. “P.2.137 Can the PANSS cognitive factor be a validsurrogate for neurocognon in schizophrenia?” In European Neuropsychopharmacology, 14:S292–93. Elsevier BV, 2004. https://doi.org/10.1016/s0924-977x(04)80357-2.
       Full Text
    • Keefe, R. S. E. “Treatment of cognitive deficits in first episode schizophrenia.” In International Journal of Neuropsychopharmacology, 7:S87–S87. CAMBRIDGE UNIV PRESS, 2004.
       Link to Item
    • Keefe, R. S. E. “Cognition as a key to alliance, adherence, and functional outcomes.” In International Journal of Neuropsychopharmacology, 7:S106–S106. CAMBRIDGE UNIV PRESS, 2004.
       Link to Item
    • Marquez, E. M., R. S. Keefe, S. E. Purdon, S. L. Rock, K. Alaka, S. Ahmed, and R. C. Mohs. “Is cognitive improvement with antipsychotic treatment pseudospecific?” In International Journal of Neuropsychopharmacology, 7:S394–S394. CAMBRIDGE UNIV PRESS, 2004.
       Link to Item
    • Sethuraman, G., S. Ahmed, S. L. Rock, C. A. Young, E. M. Marquez, S. E. Purdon, and R. S. Keefe. “Can the panss cognitive factor be a valid surrogate for neurocognition in schizophrenia?” In International Journal of Neuropsychopharmacology, 7:S226–S226. CAMBRIDGE UNIV PRESS, 2004.
       Link to Item
    • Hawkins, K. A., J. Addington, R. S. E. Keefe, B. K. Christensen, S. W. Woods, T. J. Miller, Q. N. Trzaskoma, et al. “Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects.” In Biological Psychiatry, 55:27S-27S. ELSEVIER SCIENCE INC, 2004.
       Link to Item
    • Keefe, R. S., C. E. Eesley, and M. P. Poe. “Defining a cognitive function decrement in schizophrenia.” In Biological Psychiatry, 55:41S-41S, 2004.
       Link to Item
    • Marquez, E., R. S. E. Keefe, S. E. Purdon, S. L. Rock, K. J. Alaka, S. Ahmed, and R. C. Mohs. “The relationship of cognition changes and other symptoms following antipsychotic treatment.” In Biological Psychiatry, 55:175S-175S. ELSEVIER SCIENCE INC, 2004.
       Link to Item
    • Narendran, R., W. G. Frankle, R. S. E. Keefe, R. B. Gil, D. Martinez, L. S. Kegeles, P. S. Talbot, et al. “PET imaging of prefrontal dopamine D1 receptors in chronic ketamine human abusers: A model for schizophrenia.” In Biological Psychiatry, 55:19S-20S. ELSEVIER SCIENCE INC, 2004.
       Link to Item
    • Sharma, T., P. D. Harvey, V. Kumari, and R. S. E. Keefe. “Cognitive enhancement in schizophrenia: Ending the therapeutic nihilism.” In Biological Psychiatry, 55:151S-151S. ELSEVIER SCIENCE INC, 2004.
       Link to Item
    • Keefe, R. S. E. “Cognition and the concept of schizotaxia.” In European Psychiatry, 19:114S-114S. EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2004.
       Link to Item
    • Hawkins, K. A., J. Addington, R. S. Keefe, B. Christensen, S. W. Woods, T. J. Miller, Q. N. Trzaskoma, A. Breier, R. B. Zipursky, and D. O. Perkins. “Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects.” In Schizophrenia Research, 67:205–205, 2004.
       Link to Item
    • Keefe, R. S. E. “The functional hurdle: Connecting through cognition.” In Schizophrenia Research, 67:277–277. ELSEVIER SCIENCE BV, 2004.
       Link to Item
    • Keefe, R. S. E., L. J. Seidman, B. Christensen, R. M. Hamer, and D. Yurgelun-Todd. “Neurocognitive effects of olanzapine and low-dose haloperidol: A two-year treatment study in first episode psychosis.” In Schizophrenia Research, 67:206–206. ELSEVIER SCIENCE BV, 2004.
       Link to Item
    • Keefe, R. S. E., T. E. Goldberg, P. D. Harvey, J. M. Gold, M. Poe, and L. Coughenour. “The brief assessment of cognition in schizophrenia: Reliability, sensitivity, and comparison with a standard neurocognitive battery.” In Schizophrenia Research, 67:263–263. ELSEVIER SCIENCE BV, 2004.
       Link to Item
    • Marquez, E. M., R. S. E. Keefe, S. E. Purdon, S. L. Rock, K. J. Alaka, S. Ahmed, and R. C. Mohs. “Is cognitive improvement with antipsychotic treatment pseudospecific?” In Schizophrenia Research, 67:207–207. ELSEVIER SCIENCE BV, 2004.
       Link to Item
    • Mohs, R. C., K. J. Alaka, R. S. E. Keefe, S. E. Purdon, S. L. Rock, H. Wei, E. M. Marquez, and S. Ahmed. “Functional outcomes and characteristics of olanzapine cognitive super-responders.” In Schizophrenia Research, 67:207–8. ELSEVIER SCIENCE BV, 2004.
       Link to Item
    • Keefe, R. S. E., L. J. Seidman, B. K. Christensen, R. M. Hamer, D. A. Yurgelun-Todd, R. R. J. Lewine, M. M. Sitskoorn, T. Sharma, M. Tohen, and J. A. Lieberman. “Neurocognitive effects of olanzapine and low-dose haloperidol: A two-year treatment study in first episode psychosis.” In Biological Psychiatry, 53:26S-26S. ELSEVIER SCIENCE INC, 2003.
       Link to Item
    • Yurgelun-Todd, D. A., P. F. Renshaw, H. Wei, R. S. E. Keefe, H. C. Charles, M. Tohen, L. J. Seidman, et al. “Improved attention is associated with reductions in frontal lobe lactate levels in first episode psychosis.” In Biological Psychiatry, 53:156S-156S. ELSEVIER SCIENCE INC, 2003.
       Link to Item
    • Breier, A., R. S. Keefe, C. A. Young, S. E. Purdon, J. M. Gold, and K. L. Davis. “A one-year double-blind comparison of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in patients with schizophrenia.” In Schizophrenia Research, 60:274–75. Elsevier BV, 2003. https://doi.org/10.1016/s0920-9964(03)80434-6.
       Full Text
    • Keefe, R., L. J. Seidman, B. Christensen, R. M. Hamer, D. Yurgelun-Todd, R. Lewine, M. Sitskoorn, T. Sharma, M. Tohen, and J. A. Lieberman. “Neurocognitive effects of olanzapine and low-dose haloperidol: A two-year treatment study in first episode psychosis.” In Schizophrenia Research, 60:289–289. Elsevier BV, 2003. https://doi.org/10.1016/s0920-9964(03)80477-2.
       Full Text
    • Yurgelun-Todd, D. A., P. F. Renshaw, H. Wei, R. S. Keefe, H. C. Charles, M. Tohen, and J. A. Liebermann. “Improved attention is associated with reductions in frontal lobe lactate levels in first episode psychosis.” In Schizophrenia Research, 60:318–318. Elsevier BV, 2003. https://doi.org/10.1016/s0920-9964(03)80271-2.
       Full Text
    • Keefe, R. S., L. J. Seidman, B. K. Christensen, D. A. Yurgelun-Todd, R. R. Lewine, M. M. Sitskoorn, and J. A. Lieberman. “Treatment of neurocognitive deficits with olanzapine or low-dose haloperidol in first episode psychosis.” In Schizophrenia Research, 49:234–234, 2001.
       Link to Item
    • Keefe, R. S. E., A. M. Bollini, M. C. Courtney, W. H. Wilson, and J. P. McEvoy. “Successful treatment of self-monitoring deficits predicts psychotic symptom decrease.” In Schizophrenia Research, 36:172–172. ELSEVIER SCIENCE BV, 1999.
       Link to Item
    • Roitman, S. E. L., R. S. E. Keefe, V. Mitropoulou, R. L. Dupre, and L. J. Siever. “Visuospatial working memory in schizotypal personality disorder.” In Biological Psychiatry, 41:355–355. ELSEVIER SCIENCE INC, 1997.
       Link to Item
    • Roitman, S. E. L., R. S. E. Keefe, R. L. Dupre, and L. J. Siever. “Visuospatial working memory in schizotypal personality disorder.” In Biological Psychiatry, 39:266–266. ELSEVIER SCIENCE INC, 1996.
       Link to Item
    • Keefe, R. S. E., S. E. L. Roitman, R. L. Dupre, and P. D. Harvey. “Laboratory and clinical tests of spatial working memory.” In Schizophrenia Research, 18:XIII7–XIII7. ELSEVIER SCIENCE BV, 1996.
       Link to Item
    • DAVIDSON, M., I. BERMAN, R. S. KEEFE, K. DUVVI, and M. PONTECORVO. “RISPERIDONE IN ELDERLY SCHIZOPHRENIC-PATIENTS.” In Schizophrenia Research, 11:197–197, 1994.
       Link to Item
    • EPSTEIN, J. I., R. S. E. KEEFE, P. D. HARVEY, R. C. MOHS, S. E. L. ROITMAN, M. DAVIDSON, and L. J. SIEVER. “THE EXTENT OF WORKING-MEMORY DEMANDS PREDICTS RESPONSE TO NEUROLEPTIC MEDICATION ON CONTINUOUS PERFORMANCE TESTS.” In Schizophrenia Research, 11:153–54. ELSEVIER SCIENCE BV, 1994.
       Link to Item
    • KEEFE, R. S. E., C. BLUM, P. D. HARVEY, M. DAVIDSON, S. E. ROITMAN, and K. L. DAVIS. “WORKING-MEMORY DEFICITS IN SCHIZOPHRENICS WITH SEVERE SELF-CARE DYSFUNCTION.” In Schizophrenia Research, 11:158–158. ELSEVIER SCIENCE BV, 1994.
       Link to Item
    • DEVEGVAR, M. L., R. S. E. KEEFE, J. MOSKOWITZ, S. LEES, O. KALUS, P. KNOTT, R. L. TRESTMAN, and L. J. SIEVER. “PERFORMANCE ON TESTS SENSITIVE TO FRONTAL-LOBE DYSFUNCTION AND DEFICIT-LIKE SYMPTOMS IN SCHIZOTYPAL PERSONALITY-DISORDER.” In Biological Psychiatry, 33:A101–A101. ELSEVIER SCIENCE INC, 1993.
       Link to Item
    • KEEFE, R. S. E., C. BLUM, D. M. MERHIGE, S. E. LEES, D. M. ZOLOT, M. DAVIDSON, P. D. HARVEY, and K. L. DAVIS. “TASKS FROM MONKEY CORTEX STUDIES AND SPECIFIC PREFRONTAL DYSFUNCTION IN SCHIZOPHRENIA.” In Biological Psychiatry, 33:A92–A92. ELSEVIER SCIENCE INC, 1993.
       Link to Item
    • KEEFE, R. S. E., R. C. MOHS, J. M. SILVERMAN, M. F. LOSONCZY, M. DAVIDSON, T. B. HORVATH, and K. L. DAVIS. “CHARACTERISTICS OF KRAEPELINIAN SCHIZOPHRENIA AND THEIR RELATION TO PREMORBID SOCIOSEXUAL FUNCTIONING.” In Neuroleptic Nonresponsive Patient : Characterization and Treatment, edited by B. ANGRIST and S. C. SCHULZ, 27:1-+. AMER PSYCHIATRIC PRESS, 1990.
       Link to Item
• Teaching & Mentoring
• 

  Recent Courses

  • NEUROSCI 496: Research Independent Study 4 2020
• Scholarly, Clinical, & Service Activities
• 

  Outreach & Engaged Scholarship

  • Summer Neuroscience Program Mentor. Summer Neuroscience Program. 2019  2019

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.